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ABSTRACT
More than one-third of all Magnetic Resonance Imaging (MRI) scans employ imageenhancing contrast agents to increase the differential signal intensity between diseased and normal
tissue. Because current clinical contrast agents exhibit low relaxivity (mM-1 s-1), low dose
efficiency, and rapid secretion, we have designed a group of protein-based MRI contrast agents
with multiple gadolinium binding sites. In this study, the developed purification method for Class
ProCA-3 agents allows for a quick and cost-effective way to abstract up to 109 mg of pure, soluble
protein from a 1L E. Coli cell pellet devoid of DNA or RNA “contamination” for extensive animal
studies. Circular dichroism far-UV spectra ensure the metal stability of the agents, revealing
maintenance of their native α-helical structure in the presence and absence of metal ions.
Furthermore, substantial evidence supports the high dose efficiency of these agents, exhibiting up

to five folds higher relaxivity than their analogous commercial competitors.
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1. INTRODUCTION
1.1. Modern Methods for Medical Imaging
1.1.1. Background
Medical imaging is a clinical discipline referring to the techniques and processes used to
create in vivo images of the human body for clinical applications or medicinal science [1]. In its
broadest sense, the incorporation of radiology, medical photography, nuclear medicine,
investigative radiological sciences, endoscopy, thermography and microscopy allows this
division of the medical field to improve diagnoses and medical care for patients [1-2]. When
applied effectively, medical imaging enables less-invasive prognosis and diagnosis, detects
disease at its earliest and most curable stage, and allows for decreased post-treatment disability,
leading to greater patient comfort and improved treatment selection. Thus, this standard of
modern medical care not only “continues to empower doctors and medical professionals to view
the human body and its organ systems with ever increasing clarity and accuracy” but as a result,
has the potential to drastically reduce the cost of healthcare by shortening hospital stays due to
faster recovery times. This is evidenced by fewer pre- and post-operative complications [2].
Therefore, the clinical and medicinal scientific communities are actively developing a number of
different imaging techniques, striving to improve their role in disease prognosis, diagnosis, and
treatment (Figure 1.1).
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Figure 1.1. Summary of current clinically applied imaging techniques for disease diagnosis.

The availability of a wide variety of imaging techniques allows the physician and
relevant medical staff to optimize patient treatment outcomes. In most cases, one or more of the
techniques are combined with another to effectively diagnose and treat a patient [2].
Although medical imaging technologies provide a wide range of clinical and patient
benefits, many of the techniques use X-ray radiation (X-rays and CT scans), posing dosedependent risks to patients. The “approach taken by the FDA is that the slight risk from radiation
is outweighed by the medical benefit of medically necessary CT scans and X-rays [2].” Still,
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there are alternative imaging techniques that function without the use of radiation and allow for
excellent resolution between diseased and normal tissue. For example, like Computed
Tomography (CT), MRI also has the ability to create a two- and three-dimensional image of a
thin slice of the body. However, unlike CT, MRI does not involve the use of ionizing radiation
and is therefore not associated with the same health hazards such as the possibility of inducing
cancer due to absorbed X-rays. Additionally, in contrast to X-ray and CT methodologies, there
are no limitations to the number of MRI scans a patient can receive [1]. Although MRI can
provide high-resolution images via optimized instrumental parameters and pulse sequences, it
has a low sensitivity and achieves better images with supplementation of a contrast agent that
increases the signal to noise ratio detected by changes in water relaxivity. Thus, the development
of MRI contrast enhancing agents proves as an excellent technique to further improve medical
imaging and thus medical diagnoses and treatment [3].
1.1.2. Principles of MRI and the Use of Contrast Agents
MRI is a non-invasive nuclear magnetic resonance (NMR) imaging technique that exploits
the magnetic properties of hydrogen and its interaction with both a large external magnetic field
and radiowaves to produce high resolution three-dimensional images of the body for disease
diagnosis [4]. Although biological tissues are predominantly 12C, 16O, 1H, and 14N, hydrogen is
the most abundant [5]. The majority of hydrogen protons observed in clinical imaging are of
water molecules because they “have a significant magnetic moment and are nearly 70%
abundant in the human body” [4-5]. As will be later explained, the varying molecular structures
and the amount of hydrogen in various tissues affect how the protons behave in an external
magnetic field and thus allow for potential delineation between different tissues.

3

The principles detailing the mechanism behind MRI signals are complex. From a simplified
“classical” view, the nucleus of an atom is composed of subatomic particles protons and neutrons
that spin about their axis [4]. More relevant to MRI signals, each nuclei of the hydrogen atoms in
solution contain a single proton spinning about its axis, producing an angular momentum (J) and
a magnetic moment (µ) (Figure 1.2) [4].

Figure 1.2. Simplified schematic illustration of the intrinsic properties of the hydrogen proton in
its original state. (A) Hydrogen proton spinning about its axis. (B) Generated angular momentum
from the proton spin.
The following equations are descriptive of the angular momentum and the magnetic moment:
J=

mω = mvr

(Equation 1.1)

where m is the mass of the proton, v is the velocity of the proton, and r is the radius or distance
of the proton from the fulcrum [5], and
µ = τmax / B

(Equation 1.2)

where τmax is the maximum torque generated and B is the magnetic field generated by the
movement of the proton [5].
The angular momentum and magnetic property of the nuclei mentioned above stems from the
mass and positive charge of the proton. Nuclei containing an even number of protons and
4

neutrons possess a net angular momentum of zero while those with an odd mass or odd atomic
number (protons) possess a certain angular momentum and have net spins of one of two possible
orientations characterized by magnetic quantum number of ± 1/2. For the purposes of MRI and
NMR, atoms with paired spins tend to cancel so atoms containing an odd number of protons (like
hydrogen) or neutrons are ideal for observing changes in the local magnetic field [5]. These net
spins generate small magnetic fields due to their vibrational and rotational motions, giving rise to
the magnetic moment. The ratio between the angular momentum and magnetic moment of the
nuclei gives rise the gyromagnetic ratio (γ), a constant specific to each magnetically active nuclei
(Equation 1.3) [5]. The gyromagnetic ratio of hydrogen is 42.6 MHz/Tesla [6].
µ=γJ

(Equation 1.3)

In the absence of an external magnetic field, these charged nuclei are in a lower energy
level and have randomly oriented spins of equal energy. When an external magnetic field (B0) is
applied, the axis of rotation of the nuclei will precess around that of the applied magnetic field.
The frequency of precession is termed Larmor frequency, a parameter that must be optimized for
efficient relaxation of a contrast agent [7]. Subsequently, in this excited state, the spins of the
nuclei will align parallel or antiparallel (with or opposed) to the magnetic field. Combined with
the magnetic and electromagnetic fields, MRI uses non-ionizing radiation radiowaves in the
form of a radiofrequency pulse (RF) to manipulate the magnetization of protons and perturb their
alignment to the external magnetic field. As the radiofrequency pulse is removed, the spins of the
nuclei decay from the higher energy state to their lower energy state through a process termed
relaxation. It’s important to note that there are radiofrequency pulse sequences designed to
highlight T1 and T2 changes, two distinct relaxation processes [8]. The change in “distribution
of the magnetic moments of the protons from random to directed and their return to normal” via
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relaxation constitutes the MRI signal [8]. The basic principles of MRI are summarized in Figure
1.3.

Figure 1.3. Simplification of the basic principles underlying MRI.
There are two dominant relaxation processes: spin-lattice (longitudinal) relaxation and
spin-spin (transverse) relaxation [9]. The nuclei spins aligned parallel or perpendicular to the
external magnetic field are generally dominated by spin-lattice relaxation time T1. The lattice is
descriptive of the sample in which the nuclei are held. The lattice field results from the magnetic
field caused by the vibrational and rotational frequencies of the nuclei [9]. Components of the
lattice field can interact with high energy state nuclei and cause them to lose energy, relaxing
them back to their lower energy state. The average time -it takes for the higher energy state
nuclei to relax to a lower energy state with respect to the lattice field is termed longitudinal
relaxation time T1 and is dependent on the gyromagnetic ratio of the nucleus and the mobility of
the lattice [9]. Not only are the spins of nuclei in the presence of an external magnetic field
influenced by components of the lattice field, but also by neighboring nuclei with identical
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precessional frequencies but differing magnetic quantum states. Though there is no net change in
Boltzmann distribution of the nuclei, a nucleus in the lower energy level will be excited while an
excited nucleus relaxes to the lower energy state. The average time it takes for the higher energy
state nuclei to relax to a lower energy state with respect to neighboring nuclei is termed
transverse relaxation time T2 [9].
Because the detection sensitivity of MRI is low, it often requires a contrast agent to
enhance the signal intensity related to the relaxation rate of water protons [8]. The term
relaxivity describes how effective a contrast agent is at enhancing the signal intensity by
shortening proton relaxation times. Contrast agents influencing the relaxation times of water
protons must be paramagnetic, those found amongst the transition metals and lanthanides,
meaning they possess a number of unpaired electrons. Here, proton relaxivity is directly
proportional to the efficiency of the paramagnetic ion to enhance the relaxation rate of water
protons [8]. Gadolinium, bearing seven unpaired electrons, has been found to exhibit the
strongest effect of all elements on T1. This is due to the dipole-dipole interactions between
proton nuclear spins and the fluctuating local magnetic field caused by the unpaired electron
spins of gadolinium [8]. Because free ions of heavy metals are toxic, lanthanides are typically
complexed with a suitable metal chelator/ligand. When the metal is bound to the chelator, it
gives rise to a contrast agent capable of influencing water relaxation.
1.1.3. Factors Contributing to MRI Relaxivity
There are a number of molecular parameters of contrast agents that govern relaxivity:
rotational diffusion, inner- and outer/second-sphere hydration (q), water exchange rates (kex),
ion-proton distances, and the electronic properties (Tie) of the paramagnetic ion [8]. The strength
of the applied magnetic field (B0) and solution viscosity also play a role in relaxation processes.
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Proton exchange rate, rotational correlation time, electronic relaxation times, Gd-proton
distance, and hydration number directly influence the inner sphere proton relaxivity [8]. If the
proton exchange is very slow relative to the relaxation rate of the coordinated protons to
gadolinium, then it will become a limiting factor, hampering optimal relaxation. If the proton
exchange is fast relative to the coordinated protons, proton relaxivity will be largely determined
by the relaxation rate of the coordinate protons [8].
Maximum relaxivity is attained when the correlation time (τci) equals the inverse proton
Larmour frequency (ωi) [8]. The correlation times characteristic of the relaxation processes are
as follows:
1/τci = 1/τR + 1/Tie + 1/τm = ωi, where i = 1, 2

[8].

(Equation 1.4)

More importantly, the rotational correlation time (τR), proton exchange (kex = 1/τm), and
electronic relaxation rates (T1,2e) must be optimized simultaneously to achieve maximum
relaxivities. Equation 1.5 addresses the effects of inner sphere relaxivity and how manipulation
of its terms can increase the overall relaxivity of a contrast agent.
r1IS = (q/[H2O])/ (T1m + τM)

[8, 10]

(Equation 1.5)

where r1IS is the relaxivity due to the inner sphere of water surrounding a paramagnetic metal
ion, q is the hydration number, [H2O] is the water concentration in mM, T1m is the T1 of the
water hydrogen in the inner sphere, and τM is the water residency time (τM = 1/kexchange of water
in the inner sphere). This equation reveals that an increase in hydration (q) or decrease in T1m or
τM can increase the overall relaxivity of a contrast agent [10]. However, the FDA approved
gadolinium-based contrast agents have not effectively optimized these parameters.
1.2. Commercial MRI Contrast Agents and Development
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Currently, it has been estimated that 40-50% of all MR images are supplemented with a
contrast agent [11]. Gadolinium-based contrast agents are implicated to achieve a number of
these images. The six FDA approved commercial gadolinium-based MRI contrast agents are T1weighted agents, meaning they yield brightened images when introduced into a system (Figure
1.4).

Figure 1.4. FDA Approved Commercial Contrast Agents [12].
The basic chelate design ranges from linear to acyclic structures. Because of their enhanced
thermodynamic stability and kinetic inertness, Gd3+-based MRI contrast agents derived from
DOTA-like macrocyclic ligands have advantages over their linear counterparts (DTPA) [13].
Overall, these small molecular Gd-chelates maintain relaxivities of 4-6 mM-1 s-1 [14]. However,
these agents have theoretically attainable relaxivity values of over 100 mM-1 s-1 (Figure 1.5A). It
has been proposed that they fail to reach their maximum relaxivity due to their fast rotation time
(100 ps) and slow water exchange in the inner sphere (Figure 1.5B) [3, 8].
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Figure 1.5. The need for improved MRI gadolinium-based contrast agents. (A) Low relaxivity of
commercial contrast agents compared to theoretical values. (B) Explanations for low observed
relaxivity for commercial agents [7-8, 15].
Furthermore, the aforementioned contrast agents are only effective at high concentrations
(>0.1 mM) [10]. Currently, the average clinical injection dosage of commercial contrast agents is
approximately 500 mM/kg at an injection rate of 2-3 mL/s to achieve high sensitivity to the
changes in water relaxation [14]. Even higher doses are required for imaging of blood vessels in
Magnetic Resonance Angiograpy (MRA) [14]. Because of their small size, the systemic
retention time of these agents is relatively short, maintaining a half-life of 1.5-2 hours in healthy
adults and thus requiring a large dose to achieve an enhanced image [14]. However, in patients
with kidney disease, the renal clearance is significantly decreased. Studies have shown that
kidney-impaired patient exposure to gadolinium-based contrast agents has been linked to local
necrosis at the injection site and nephrogenic systemic fibrosis (NSF) or nephrogenic systemic
dermopathy (NSD) due to their weak binding affinity to gadolinium leading to the release of free
gadolinium in the body and the accumulation of the contrast agent in the kidney (lack of proper
excretion) [14].
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Figure 1.6. Visible symptoms or signs of NSF/NSD [16-17].
NSF/NSD is a life-threatening disorder that may develop over a short period of days to several
weeks (full development) [18]. As shown in Figure 1.6, it is characterized by swelling and
tightening of the skin, usually limited to the extremities, and severely affected patients may be
unable to walk, or fully extend the joints of their arms, hands, legs, and feet [18]. More
specifically, the release of free gadolinium correlated with NSF has been known to cause many
toxic systemic effects such as inhibiting calcium-flux-dependent physiological processes,
blocking many voltage-gated calcium channels at nano- to micro-molar concentrations, and
depressing the reticuloendothelial system [14, 19]. For this reason, in May 2007, the FDA issued
a black box label warning to be placed on five of the six approved gadolinium-based contrast
agents (with the exception of Dotarem®) in the United States, warning health professionals and
patients of the association between the use of gadolinium-based contrast agents and NSF [20].
Because of their low dose efficiency due to low relaxivity and to low retention time and health
hazards, there has been considerable effort to effectively improve contrast agent design and
enhance the sensitivity of MRI devoid of such toxic effects. Agents with higher relaxivities and
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optimal retention times can be detected at lower doses, providing greater signal contrast images
at equivalent doses to commercial compounds with lower relaxivity [10].
The demand for the development of improved MRI contrast agents has become increasingly
widespread. The two primary approaches taken by the scientific community to increase
molecular relaxivity are optimization of the aforementioned molecular parameters that govern
relaxivity and linking multiple gadolinium tetraazacyclododecanetetraacetic acid (DOTA) or
diethylenetriaminopentaacetic acid (DTPA) complexes together (Figure 1.7) [10].

Figure 1.7. Current MRI contrast agent development.
These newly developed classes of contrast agents predominantly address the rapid rotational
time of commercial agents by covalently linking chains of Gd-DTPA or Gd-DOTA to larger
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biomolecules such as dendrimers, carbon nanotubes, nanoemulsions, liposomes, micelles, or
proteins [21]. However, while these agents address the overall rotational time associated with
molecular tumbling in solution, they do not achieve significantly higher relaxivities than the
commercial analogues due to their intrinsic internal mobility and restricted water exchange rate
[3]. Furthermore, their large particle size (10-100 nm) prevents them from being properly
excreted from the body, raising greater toxicity concerns of gadolinium-based agents. As a
result, a novel class of protein-based MRI contrast agents has been designed with high dose
efficiency due to higher relaxivity, strong metal stability, and optimized pharmokinetics.
1.3. Criteria for Contrast Agent Design
Because contrast agents have the potential to be invaluable clinical probes for enhancing
magnetic resonance images, it is of crucial importance to design an agent with a high relaxivity,
strong binding affinity to gadolinium versus other physiological metal ions, and high metallostructural stability. The achieved higher relaxivity agent will not only improve the sensitivity of
MR imaging, but also greatly reduce the amount of agent necessary to achieve significant
contrast. Thus, the dose efficiency of the contrast agent is increased, providing higher contrast
capability due to the incorporation of multiple designed gadolinium-binding sites into a scaffold
structure and to obtaining an optimal τR in the nanosecond range. The strong binding affinity of
the designed contrast agent to gadolinium will confer high metal selectivity to avoid potential
adverse competition from other systemic metals and alleviate many of the toxic concerns
associated with the release of free gadolinium into the system. Furthermore, heightened
structural tolerance of mutations, high blood serum stability, and high solubility will reduce the
potential instability of the scaffold contrast agent design. To add to the previously mentioned
determining factors in design, the developed class of contrast agents must have no reported
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interactions with other biomolecules, possess an optimal systemic retention time to successfully
acquire an MR image, and be properly excreted via the kidneys or liver metabolism.
1.4. Theory Preceding the Development of Protein-Based Contrast Agents
Dr. Jenny Yang’s lab of Georgia State University has developed a novel approach to
designing improved contrast agents via protein engineering. Protein-based MRI contrast agents
offer a number of advantages compared to the aforementioned commercial analogs. To improve
relaxivity, proteins can be modified to achieve an optimal metal-site rotational time of 10ns,
optimal hydration of inner and second-sphere hydration, and optimal water exchange rates of 130ns [3, 8]. The obtained higher relaxivity will improve the dose efficiency associated with
gadolinium-based MRI contrast agents. Therefore, a lower concentration and volume of agent
will be required to significantly improve the contrast to noise ratio of MR images, reducing the
potential for the toxic effects associated with NSF/NSD. Their modifiable, compact molecular
size (12 kDa) is suitable for sufficient intravascular distribution and easy renal excretion.
Additionally, choosing a stable host protein tolerant of various mutations, affords the opportunity
to design gadolinium-binding sites into its structure and confer metal selectivity via tuned metal
binding affinity [3]. Improved solubility and reduced immunogenicity can be achieved by
covalently attaching polyethylene glycol (PEG) chains to lysine or cysteine residues of the
protein [22]. Using this approach to develop improved agents, Dr. Yang’s lab previously
designed and conducted significant studies on Class ProCAi-CD2 agents (i = 1, 2, 3….9). These
agents were developed through the introduction of single high-coordination gadolinium binding
sites into stable CD2 protein using amino acid residues and water molecules as metal
coordinating ligands [3]. The designed proteins showed strong selectivity for gadolinium over
physiological metal ions such as calcium, zinc, and magnesium, exhibited a 20-fold increase in
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T1 and T2 relaxation rate values over the conventional small-molecule contrast agents, e.g., GdDTPA, and possessed stronger contrast enhancement and longer blood retention time than GdDTPA in mice models [3]. With a new generation of contrast agents on the horizon, we hope to
address the following question: Can we design multiple gadolinium-binding site agents to further
increase contrast agent dose efficiency, increase stability, and reduce toxicity?
1.5. Designed Multi-Binding Site Contrast Agents by Protein Engineering
Dr. Jenny J. Yang’s lab specializes in two approaches to studies of calcium-binding proteins,
the design and grafting approaches. The design approach involves site-directed mutagenesis to
tune metal-binding affinities of calcium-binding proteins, conserving the number of amino acids
in their primary sequence and maintaining their structural integrity. This approach was created in
order to “develop a general methodology to design metal binding sites with high coordination
numbers such as calcium and lanthanides, understand the mechanism of calcium-regulated
biological process such as ligand-induced conformational changes in cell adhesion, and monitor
calcium signaling in vivo” [23]. The grafting approach engineers an EF-hand calcium-binding
loop into a protein to understand “site-specific metal binding affinity and selectivity of
individual calcium binding motifs and to estimate the contribution of conformational change and
cooperativity between paired EF-hand motifs” [23].
Using the design approach, two gadolinium-binding sites were engineered into a stable host
protein, which in its native state, has little to no reported interactions with other biomolecules. It
is with great hopes that the increased number of binding sites will enhance the measured
relaxivity compared to commercial agents, and thus improve the dose efficiency. Provided the
binding affinity of gadolinium to the protein is significantly strong, the toxic effects associated
with the release of free gadolinium into the system are greatly reduced.
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1.6. Parvalbumin as an Excellent Scaffold for Engineering Multiple Gadolinium Binding Sites
Parvalbumin is a small, 12 kDa acidic protein ubiquitously distributed throughout the
vertebrate phylum [24-25]. The mammalian form is found in fast twitch muscle fibers, neuronal
cells, and several endocrine glands [25]. Furthermore, parvalbumin has two isoforms: α and β.
Though both forms have a conserved helix-turn-helix motif, the α-form maintains 109 amino
acids and is believed to serve mainly as a cytosolic calcium-buffering protein with no known
interacting partners [26-27]. This six α-helical protein, helices termed A through F, contains
three EF-hand motifs, only two of which functionally bind calcium (CD and EF sites) (Figure
1.8). The β-form, or better termed oncomodulin, maintains 108 amino acids, functioning more so
as a calmodulin-like enzyme ―― often active during cellular proliferation [24, 27]. This form
of parvalbumin possesses two different metal binding domains, one calcium specific and one
calcium/magnesium mixed site [27]. For the purposes of this project, we will mainly focus on
studies of the rat derived α-form.

Figure 1.8. Pymol structure of rat-derived α-parvalbumin.

16

The CD site EF-hand motif of parvalbumin is modified through single mutations within a
calcium-binding site. Maintaining pentagonal bipyramidal geometry (Figure 1.9), its residues 1,
3, 5, 7, 9, and 12 are the conserved residues subject to mutagenesis [28]. Because calcium and
gadolinium have comparable ionic radii and gadolinium, it is with great hopes that the increased
charge of gadolinium will allow mutants to bind this metal with a much larger affinity than
calcium. To enhance gadolinium-binding affinity and allow for experimental analysis, various
mutations were introduced into the binding domains of parvalbumin (Figure 1.9).

Figure 1.9. Summarizing the CD and EF binding domains of α-parvalbumin and their pentagonal
bipyramidal geometries.
Residue 103, located outside the EF binding domain, was mutated from phenylalanine (F) to
tryptophan (W) in order to complete terbium fluorescence experiments. Residue 56, located in
position five of the CD EF-hand binding site, was mutated from serine (S) to aspartic acid (D) to
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increase the proteins gadolinium-binding affinity. Residue 60, also located in the CD binding site
but in position nine, was mutated from glutamic acid (E) to aspartic acid (D) to increase
gadolinium-binding affinity and allow for the incorporation of a water molecule into the binding
site. This incorporation should theoretically enhance the water exchange rate associated with the
gadolinium-binding site and increase the relaxivity. The same can also be said for residue 99,
located in the EF binding site, mutation from glycine (G) to aspartic acid (D). It is proposed that
these mutations will not perturb the conformational fold and can effectively bind gadolinium
with little negative competition from calcium or other biological metal ions at their respective
physiological concentration. However, this must be further investigated in future experiments.
Single and double mutations were introduced into the metal binding sites to observe the intrinsic
metal selectivity properties of mutant forms of parvalbumin.
In this thesis, only single mutant forms of parvalbumin were studied. The significance of
each mutation was previously discussed. Here, ProCA-30 represents wildtype parvalbumin.
ProCA-31 is often referred as pseudo-wildtype parvalbumin because it bears a F103W mutation.
ProCA-32 bears a S56D and F103W mutation. ProCA-33 encompasses an E60D and a F103W
mutation. Collectively, these mutant proteins, or rather contrast agents, comprise four of many
members of Class ProCA-3 agents (Table 1.1).
1.7. Overview of Objectives
In order to understand the key determinants for calcium-binding affinity and metal
selectivity, the initial objective is to characterize the folding and metal-binding properties of
parvalbumin. Based on the differentiation between 54 amino acid sequences, the human and rat
α-forms maintain conserved residues within their EF-hand binding sites. Thus, characteristic in
vitro studies of the rat derived form can allow one to draw conclusions about the functional
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properties of the human form. The short-term goals of this project are to 1) isolate pure,
functional rat parvalbumin (rPV) and its mutagenic components, 2) perform structural studies of
rPV and its mutants by circular dichroism, and 3) complete calcium titration and metal binding
competition experiments using fluorescence. The long-term goal is to control protein function by
tuning metal binding affinities and eventually develop rPV and/or its mutants as site specific
diagnostic and therapeutic MRI contrast agents.
As part of this new class of MRI contrast agents, the engineered mutagenic form of
parvalbumin will have improved relaxivity through the binding of gadolinium and exhibit strong
stability against pH changes. Moreover, it should be structurally tolerant of mutations, have a
selective binding affinity for gadolinium, and maintain a molecular size suitable for intravascular
distribution and easy renal excretion [3]. Coupled with low toxicity and high solubility, the
ability to mass produce pure quantities of this protein at reduced costs will prove advantageous.
This thesis will focus primarily on the expression and purification, metal-dependent structural
changes, and relaxivity of four members of Class ProCA-3.
In chapter 2, the methods implemented for studies of Class ProCA-3 agents will be
discussed. In chapter 3, the E. Coli expression and optimized purification of the designed
contrast agents will be heavily expounded upon. In chapter 4, structural analysis of the purified
agents in the presence of magnesium, calcium, gadolinium, and terbium and the effect that salt
ions play on the structure will also be discussed. Chapter 5 will detail the measured in vitro
relaxivities of Class ProCA-3 agents and their binding mode with gadolinium. Chapter 6
discusses the significance of this thesis and the future application of Class ProCA-3 agents. The
discussed members of this class are summarized in Table 1.
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Table 1.1. Summary of the discussed members of Class ProCA-3 agents.
Designed
Mutation
Location
Molecular
Contrast Agent

Weight

Pro CA-30

N/A

N/A

~ 11.925 kDa

ProCA-31

F103W

Just outside EF

~ 11.964 kDa

site
ProCA-32

S56D, F103W

CD site (pos. 5)

~ 11.992 kDa

ProCA-33

E60D, F103W

CD site (pos. 9)

~11.950 kDa
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2. MATERIALS AND METHODS
2.1. Cloning and Transformation
The DNA sequences for expression of the aforementioned contrast agents were cloned into
pET-22b(+) by senior PhD student David Xue. The experimental details outlined in this thesis
began at the level of transformation. Transformation is a commonly used technique to introduce
genetic alterations into a host cell through the uptake of foreign DNA [29]. More specifically,
the gene encoding for parvalbumin and its mutants were inserted into the pET-22b(+) vector
between the Nde I and Xho I restriction enzyme sites and collectively transfected into E.Coli
BL-21 pLys cells. (Figure 2.1).

Figure 2.1. pET-22b(+) vector for Class ProCA-3 overexpression [30].
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This particular bacterial system is ideal for overexpression of the designed proteins because
it has the ability to produce large amounts of RNA, amplifying the translation of wildtype or
genetically engineered mutant genes [29]. A volume of 0.5 μL of desired mutant DNA was
mixed with 50 μL of thawed E. Coli BL-21 pLys competent cells with a pipette using an “up and
down” pipetting technique and placed on ice for thirty minutes. The samples, including the
negative controls containing only competent cells, were placed in a 42 ºC water bath for 90
seconds and placed on ice for an additional 2 minutes. A volume of 50 μL of LB was added to
the samples and placed in the incubator at 37 ºC for 30 minutes. The samples were then streaked
out with sterile L-shaped spreaders onto LB ampiscillin plates and left in the 37 ºC incubator
overnight. The following morning yielded evidence of a large number of isolated colonies
containing the transfected parvalbumin plasmid. One colony of each variant would be later used
for innoculation.
2.2. Protein Overexpression
2.2.1. Pilot Expression
A recurrent problem with the purification of soluble, tagless proteins, such as those of Class
ProCA-3 agents, is the inability to eliminate DNA/RNA contamination. It is well known that
insoluble proteins are effectively isolated from coexisting nucleic acids via inclusion body
formation. Therefore, to improve the purification process and increase the yield of isolated
protein, pilot expression procedures were implemented with hopes of extracting ProCA-30 and
its mutants from the inclusion bodies, since DNA normally lies in the supernatant following
centrifugation of cell lysate. It has been proposed that certain bacterial strains have a preference
to form more inclusion bodies than others at a specific temperature. Therefore, choosing one of
these strains to express the protein might allow us to extract it from the cell pellet. In an attempt
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to isolate the protein from nucleic acids following cell lysis, the pilot expression protocol
modified from Invitrogen’s pRSET A, B, C protocol manual was used to transform and express
ProCA-30 in three different strains using two different concentrations of isopropyl β-D-1thiogalactopyranoside (IPTG) (0.5 and 1 mM). The cell pellet following expression was
fractionated by incremental exposure to dry ice and analyzed by SDS-PAGE analysis to
determine whether PV was present in the inclusion body for the reasons previously stated.
2.2.2. Innoculation
A predetermined volume of Luria Bertani (LB) medium was prepared and autoclaved at 15
psi for 1 hour at 121 °C. Traditionally, two 1L flasks and one 250 mL flask were subjected to
this sterilization process and allowed to cool for the overexpression of each ProCA-3 agent. In
order to effectively overexpress each variant, an initial overnight growth of its cellular
expression system must be achieved. One freshly transfected colony was immersed in a 250 mL
culture of sterilized Luria Bertani (LB) medium containing 100 µg/mL of ampiscillin. Great care
was taken to minimize contamination by use of a sterilized inoculating loop and by performing
the transfer of clone to LB flask near an open flame. The flask was then placed in an
environmental shaker to incubate overnight at 37 °C at a speed of 220 to 230 rpm. The following
morning yielded a cloudy solution marked by cell growth. These cells were later to be
transferred to a freshly sterilized LB-ampiscillin medium for optimal cell growth and eventual
overexpression of the desired mutant.
2.2.3. Overexpression
A 50 mL volume of overnight culture was added to each of two 1L flasks of fresh media
containing 100 µg/mL of ampiscillin. The two 1L flasks were incubated in a 37 ºC shaker at a
speed of 220 to 230 rpm, allowing cellular growth to continue. Following induction of the
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system with IPTG to overexpress the desired protein, the cells were allowed to grow for
approximately three to four hours before reducing the incubation temperature to 25 °C at the
same speed for overnight expression. The following morning, the cultured media was subjected
to centrifugation and the cell pellet was isolated and frozen until purification methods were
implemented.
Using Shimadzu UV-Visible Spectrophotometer (UVP), the optical density of the rapidly
growing cloned cells immediately before induction (0.6000 to 0.8000 more) with inducer IPTG
and at various time points after induction was observed and recorded at 600 nm. The absorbance
readings were recorded and plotted in the Kaleidagraph 3.5 program to chart cellular growth.
Then the samples used for the UVP were saved and spun down in microcentrifuge tubes. The
supernatant was poured off and the cell pellet containing the targeted mutant was resuspended in
a sample buffer containing dithiothreitol (DTT) and beta-mercaptoethanol, which reduce the
disulfide bridges stabilizing the

protein’s tertiary structure, and sodium dodecyl sulfate (SDS),

and anionic detergent that binds strongly to and denatures the protein [25]. The samples were
boiled for ten minutes and an SDS-PAGE gel analysis was conducted. The protein is fully
denatured by this gel electrophoresis experiment and opens up in a rod-shaped form with a
number of negatively charged SDS molecules along the polypeptide chain, one SDS molecule
for every two amino acid residues of the mutant [25]. The gel was run using a marker of known
molecular weight (68, 29, 14.3, and 6.5 kDa) to chart where the target contrast agent (~12 kDa)
was located in the resolving portion of the gel following its migration through the stacking
portion, which “concentrates the protein sample into a sharp band before it enters the main
separating gel…allowing relatively large sample volumes of the mutant (10 μL) to be applied to
the gel without any loss of resolution” [31]. Once the samples had completely migrated to the
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bottom of the resolving portion of the gel, the entire gel was stained with a Coomassie blue
reagent and destained with a buffer containing methanol, acetic acid, and deionized water. The
protein bands are visible after destaining the gel. It is generally accepted that a “very faint
protein band is equivalent to about 0.1 μg of protein” [31]. Figure 2.2 summarizes the expression
procedures implemented.

Expression Procedure:
Transfer

Shake overnight at
37 C

Transformation

pET 22b‐CA3 into
E. Coli
BL‐21 (De3) pLys
competent cells

1 colony
250 mL fresh LB

50 mL LB

1 L fresh LB

Shake at 37 C to the
desired O.D. of 0.6 to
0.8 at 600nm

100 mg ampicillin

100 mg ampicillin

Induction
Add

IPTG
Centrifugation at
7K, 4°C, 30
minutes

Collect cell
pellet and
store at -20°C

Overexpress
protein overnight
at 25ºC

1mM per 1L LB

Figure 2.2. Summary of the Expression Procedures for ProCA3 Agents.
The most significant advantage of the overexpression of a recombinant protein is the ability
to facilitate purification of high quantities of product. Following a collection of the cell pellet
containing the desired protein from the cultured LB media, purification schemes using
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sonication/French Press, nucleic acid precipitation, and ion exchange chromatography (IEC)
were implemented to effectively extract the variant from the cells with a high degree of purity.
2.3. Tagless Purification
2.3.1. Sonication and French Press
In order to extract the contrast agent from the cultured E. Coli cells, their phospholipid
bilayer must be fractionated. There are two commonly used techniques to achieve this effect:
sonication and French press. Sonication is the act of applying high energy sound waves to
disrupt cell membranes and release cellular contents (sonoporation) [32]. Due to its simplistic
ease of operation, the sonicator is much easier to use when you have many samples.
Additionally, it gives a sample in a water bath an even and consistent vibration, allowing one to
achieve the same amount of cell breakage in each sample [32]. French pressure cell press, or
French press, is an apparatus used in biological experimentation to disrupt the plasma membrane
of cells by passing them through a narrow valve under high pressure [33]. Once past the valve,
the pressure drops to atmospheric pressure and generates shear stress that disrupts the cells.
French Press is more efficient and doesn’t generate heat when breaking cells, but it has a
minimum volume requirement (500 µL) [33]. Depending on the volume of protein expressed,
researchers may prefer one over the other. There has been no notable difference in efficiency
between the two methods for the purposes of these experiments so both were used
interchangeably to lyse the cells.
The cell pellet from the expression of a target protein was thawed in a cool water bath and
resuspended in 30 mL of 10 mM Tris/HCl pH 7.4 buffer. The mixture was then vortexed with
100 mM phenylmethanesulphonylfluoride (PMSF), a serine protease inhibitor, and separated
into two 15 mL volumes to prepare for sonication. Protease inhibitors are necessary if the protein
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has increased susceptibility to cleavage by a variety of proteases in solution. They help preserve
the yield and quality of purified protein. There are four groups of proteases: serine, cysteine,
aspartic and metallo-proteases. Based on protein sequence and published data, one can determine
which type of protease inhibitor is best for the purification of his or her protein. The best
protease inhibitor to be used for parvalbumin purification methods was one of serine derivation.
Following its addition, each sample of protein was sonicated six times for 30 seconds, with one
minute cooling increments. The mixture was then centrifuged at 17K for 30 minutes. The
supernatant containing the soluble variant protein was collected and the cell pellet was
discarded. Samples of both the supernatant and cell pellet were taken for SDS Page gel analysis
by the previously described method within the expression protocol.
2.3.2. Nucleic Acid Precipitation
In efforts to isolate the soluble variant via tagless purification methods, DNA and RNA
contamination must be removed from the supernatant. A concentration of 1.3µM of
benzonuclease- MgCl2, an endonuclease and its cofactor that degrades all forms of DNA and
RNA while having no proteolytic activity, was added to the supernatant overnight at 4 ºC.
Endonucleases compose a class of restriction enzymes produced by bacteria that typically
recognize specific 4- to 8-base pair palindromic sequences, called restriction sites, and then
cleave both DNA strands at this site. Thus, the choice for endonuclease type was made based on
the sequence of the pET-22b(+) vector.
Previous experiments conducted prior to the Summer 2009 semester were done to determine
which concentration of streptomycin sulfate (1%, 3%, 5%, or 10%) was optimal for the removal
of nucleic acids and other proteins not thermally stable at high temperatures. It was found that
5% streptomycin sulfate concentration is optimal for nucleic acid precipitation from the protein
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supernatant following overnight cleavage of nucleic acids with benzonuclease. Thus, the process
of precipitation began with adding 5% streptomycin sulfate, a nucleic acid precipitant, to the
solution overnight at 4 ºC. The supernatant was centrifuged and the cell pellet was frozen while
subsequent steps of the procedure were applied to the resulting supernatant containing the
soluble contrast agent. Incubation in an 85 ºC water bath for 10 minutes and immersion in an ice
bath allowed for a visible precipitation of fragmented nucleic acids and proteins lacking
thermostability at such a high temperature. For thermostable proteins, the addition of nucleic
acid precipitant aids in a higher yield from purification. The extent of protein precipitation is
dependent upon the pH of solution and the ratio of precipitant to protein. Streptomycin sulfate is
generally favorable over other commercially available precipitants such as, protamine sulfate and
manganese chloride. One can also use varying concentrations of ammonium sulfate
(concentration depends on properties of protein) to precipitate desired protein from a solution.
The mixture was spun down again at 17K for 30 minutes, allowing one to collect the
supernatant and freeze the cell pellet. To lower the salt concentration introduced into the protein
supernatant system by streptomycin sulfate, the protein was dialysed in 10mM Tris/HCl pH 7.4
overnight at 4ºC and for two 2 hour sessions under the same conditions the following day in
freshly prepared buffer. Next, the supernatant was brought to a concentration of 5 mM EDTA to
remove magnesium or calcium from the variant system over a period of one hour. Because the
overall negative charge of the protein is reduced in the holo-form, the removal of metals from its
binding site hopefully increases the protein’s affinity for the chromatographic methods of
separation to be discussed. It was then filtered via a syringe through a 0.2 µM membrane and
injected onto anionic Q-column using a FPLC system. Samples of both the supernatant and cell
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pellet following cell lysis, nucleic acid precipitation, and dialysis were taken for SDS Page gel
analysis by the previously described methods.
2.3.3. Ion Exchange Chromatography
The method of chromatographic column separation using FPLC is dependent upon the
physical and chemical properties of a protein. If the protein carries a negative charge at the pH of
buffer used, as in the case with parvalbumin and its variants, the Q sepharose column, an anionic
binding column separating based on charge, is a great method for separation. Using an
Amersham Biosciences FPLC system, a 10mL volume of diluted protein supernatant (ranged
from a 1:10 to a 1:5 dilution of protein to Buffer A) was injected onto the Q column. Using
Buffer A: 10mM Tris/HCl 5mM EDTA pH 8.5 and Buffer B: 10mM Tris/HCl 5mM EDTA 1M
NaCl pH 8.5 combination, a modified FPLC separation program was implemented to elute the
desired protein at 25% concentration of Buffer B.
Initially, the contrast agent binds to the column with the introduction of Buffer A.
Theoretically, any positively charged proteins at pH 8.5 with little affinity for the column will
not bind to the column, maintaining a lower retention time than that of parvalbumin or nucleic
acids. Thus, these proteins along with smaller fragments of nucleic acids will elute from the
column in the first peak monitored by ultraviolet light at 260nm for mutants lacking a tryptophan
and at 280nm for those containing a tryptophan. As the Buffer B concentration increases to 25%,
the contrast agent will elute from the column in the second peak. The final peak eluted at 100%
of Buffer B corresponds to nucleic acids that were initially present in the sample. Previous FPLC
experimental conditions allowed for a second FPLC run during which Buffers A and B contained
3mM Ca instead of EDTA. However, this step was eliminated to reduce the number of steps
required to isolate the apo-form of the proteins for metal analysis via circular dichroism,
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relaxivity, and fluorescence. It is well known that parvalbumin binds calcium with a high affinity
and calcium. Additionally, with each successive step of the purification process, there are
subsequent consequential losses of protein. Thus, the elimination of this step may also allow for
isolation of a higher quantity of protein.
The appropriate peak observed was collected from each injection. The desired protein
fractions were concentrated down to a final resuspension in a 4 to 6 mL volume of fresh 10mM
Tris/HCl chelexed at pH 7.4. The protein was then dialysed against 10mM Tris/HCl chelex
overnight and then for two 2 hour increments the following day at 4˚C. Figure 2.3 and Figure 2.4
summarize the purification procedures.

Figure 2.3. Summary of ProCA3 Purification Procedures.
30

Figure 2.4. Summary of Purification Procedures Continued.

2.3.4. Protein Concentration Calculation
The UV absorbance of the concentrated protein was measured at its characteristic
wavelength (previously mentioned) to calculate the final yield of protein and to verify its purity
by comparing the spectra obtained to that of published data concerning the wildtype protein and
F103W mutant. The concentration was calculated through use of the Beer-Lambert law,
A = є c l,

(Equation 2.1)

where A is the measured absorbance at 260nm (phenylalanine characteristic absorbance) for
ProCA-30 and at 280nm (tryptophan characteristic absorbance) for ProCA-31, ProCA-32, and
ProCA-33, c is the protein concentration, and l is the path length of the cell (1cm). The molar
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extinction coefficient for ProCA-30 is 1600 cm-1 while that of the remaining members of Class
ProCA-3 is 7200 cm-1 [25, 34]. The protein was then stored at -20ºC.

Figure 2.5.Published UV spectrum of Parvalbumin. (A) Wildtype. (B) Parvalbumin-F103W;
Dashed line, metal-free form; solid line, Ca2+ loaded form [25, 35].
2.4. Circular Dichroism
Circular Dichroism (CD) is termed as the difference in the absorption of left- and righthanded circularly polarized light of a molecule containing one or more chiral light-absorbing
groups [36]. CD measured as a function of wavelength is termed CD spectroscopy. Circular
polarized light is converted from linearly polarized light, the sum of two linearly polarized states
(horizontal and vertical) at right angles to each other confined to a single plane, using a quarterwave plate [36]. This birefringent plate allows for the distinction between the refractive indices
seen by horizontally and vertically polarized light, slowing one of the linear components of the
beam with respect to the other so that they are one quarter-wave out of phase [36]. This produces
a beam of either left- or right-circularly polarized light, due to variances in their speed
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propagation in the medium. Projection of the resulting amplitude of the beam yields an ellipse
instead of the usual line [36].
The chiral character of the molecules measured relies on their existence as nonsuperimposable pairs of mirror images (enantiomers) [36]. Though the physical and chemical
properties of a pair of enantiomers are the same, their optical activity varies and thus allows for
delineation between the two using CD spectroscopy. Measurements carried out by the
spectrometer in the near and far ultraviolet regions of the electromagnetic spectrum monitor
electronic transitions of each chiral chromophore state of a molecule. Thus, the signal will vary
as a function of wavelength and reflects an average of the entire molecular population [36]. The
CD signal is positive if the left-circularly polarized light is absorbed to a greater extent than the
right-circularly polarized light. The signal is negative if the reverse occurs.
Though CD spectroscopy has been widely used in the study of various sizes of chiral
molecules, it has been extensively implemented in the study of large biomolecules. More
specifically, its role in secondary and tertiary structure determination of proteins has allowed
researchers to observe conformational changes due to variations in environmental conditions
such as temperature, pH, or interactions with other molecules such as metal ions. The secondary
structure is observed in the far ultraviolet range of 250 to 190 nm while the packing interactions
of the tertiary fold are observed in the near ultraviolet range of 350 to 250 nm [36]. An alphahelix absorbs negatively at 208nm and 222 nm and positively at 192 nm while a beta-sheet
structure absorbs negative at 218 nm and positive at 196 nm and a random coil absorbs positive
at 212 nm and negative at 195 nm [36].
Proteins are composed of amino acids and 19 of the 20 naturally occurring amino acids
(exception is glycine) are chiral and thus allow for observation via CD spectroscopy. Protein
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chromophores are divided into three classes: the peptide bond, the amino acid sidechains, and
any prosthetic groups [36]. For example, disulfide group of cysteine is an inherently asymmetric
chromophore as it prefers a gauche conformation with a broad CD absorption around 250 nm.
Additionally, the three aromatic side chains that occur in proteins (phenyl group of Phe, phenolic
group of Tyr, and indole group of Trp) also have absorption bands in the ultraviolet spectrum.
However, in proteins, their contribution to the CD spectra in the far UV (where secondary
structural information is located) is usually negligible [36]. Aromatic residues, if unusually
abundant, can have significant effects on the CD spectra in the region < 230 nm, complicating
analysis.
Changes in CD signal stem from changes in protein structure. These changes are often
observed in the presence of various metal ions. For example, previous studies conducted by A.
Szent-Gyorgyi investigate the citric acid (oxygen metabolism) cycle (1941) in which subsequent
electron transfers occur in eight proteins, which lead to the hypothesis that proteins act as
conductors [37]. A group of researchers isolated and purified metal-doped (Cu2O, CdO and PbO)
muscle protein from fish (Clarious batracus Lin.) and characterized its potential as
semiconducting biopolymer [37]. Initial characterization studies observed secondary structure
changes of the isolated protein in the presence of Cd, Pb, and Cu using CD (Figure 2.6).
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Figure 2.6. CD spectrum of protein with and without metal-doped (a) pro, (b) pro-Cd, (c) pro-Pb
and (d) pro-Cu [37].
The scientists wanted to ensure the structural dependence of the protein with the metal ion.
From the figure, one can observe that helicity decreased as the metals of increasing size were
added to the protein. The authors attributed this phenomenon to the slight weakening of the
hydrogen bonds caused by the insertion of larger metal ions [37]. This figure indicates that the
protein has undergone a simple transformation from twisted coil to alpha-helix. From this study
and countless others, one can see the usefulness of CD as a tool to probe changes in protein
structure. More specifically, this spectroscopic technique can be used to evaluate structural
changes induced by the binding of the ProCA3 agents to various metals.
The secondary structural changes, if any, of each agent in the presence of magnesium,
calcium, gadolinium, and terbium were analyzed. The parameters for the CD instrument were set
as follows: 0.5 nm data pitch, continuous scanning mode, 100 nm/min scanning speed, 1 sec
response, 1 nm band width, 7 accumulation for the scans. Initially, the buffer 10 mM Tris/HCl
(100 mM NaCl) chelex pH 7.4 was scanned. This spectrum was subtracted from the UV spectra
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to follow. The second sample scanned consisted of the previous buffer system of the first sample
containing 5 to 10 µM protein. The characteristic absorption of this alpha-helical protein was
noted. The addition of calcium, gadolinium, terbium, or magnesium in this system for the
consecutive samples was completed to observe any spectral changes in conformation.
Appropriate background absorptions were subtracted for the samples with added metal. Analysis
of the stability of the protein’s structure as well as its conformational behavior in the presence of
varying metal environments can be analyzed.
2.5. Fluorescence Spectroscopy
The length of time necessary for each member of Class ProCA-3 to equilibrate with
gadolinium for accurate measurement of relaxation times was unknown. Thus, fluorescence
spectroscopy was used to determine the appropriate metal equilibration time for preparing the
relaxivity samples for measurement. It is well known that the length of time required is heavily
dependent upon the binding affinity of the protein to gadolinium. Assuming that the member of
Class ProCA-3 displaying the weakest binding affinity to gadolinium will require the longest
amount of time to reach metal equilibration, ProCA-31 was chosen as the test subject. It is
important to note here that all dissociation constants were measured via terbium fluorescent
metal competition experiments by Sr. PhD researcher David Xue.
The parameters for an emission scan using the fluorimeter were set as follows: digital
configuration, λexc- 552 nm (per manufacturer’s recommendation), λem.- 560-650 nm (per
manufacturer’s recommendation), length: 90 nm, step size: 1 nm, integration: 0.2 seconds,
averages: 1, and slit widths: excitation- 0.32 and emission-0.50. A stock sample of 100µM of
ProCA-31 and 200µM of gadolinium was incubated at 37˚C over the following time points: 30
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minutes, 3 hours, and overnight. Separately, a 10µM stock of Rhodamine-5N tripotassium salt, a
weak calcium dye, was prepared in 100mM Tris/HCl 100mM NaCl chelex pH 7.44 (Figure 2.7).

Figure 2.7. Chemical structure of rhodamine-5N tripotassium salt used in fluorescence titrations
[38].
At the start of each time point, the fluorescent signal intensity of free 10µM Rhodamine-5N was
measured. Then, a calculated volume of ProCA-31-Gd3+ from the stock sample was mixed with
the 10µM Rhodamine-5N to yield a final concentration of 20µM ProCA-31 to 40µM gadolinium
concentration in an 800µL volume. A subsequent scan of this sample’s increased fluorescent
signal was measured (Figure 2.8). Next, increasing amounts of gadolinium was titrated into the
system until free Rhodamine-5N became saturated, as indicated by the absence of change in
increasing fluorescence intensity. Then, a predetermined concentration of EGTA was added to
the system to chelate the metal bound both to Rhodamine-5N and protein and decrease the
fluorescent signal back to the baseline of fluorescent intensity (Figure 2.8).
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Figure 2.8. Fluorescence spectrum of free metal titration experiment.
The pH of the dye stock sample, the stock sample, and the EGTA added sample was monitored
to ensure that the pH values remained close to the original conditions of 7.44. The maximum
intensity of each scan was recorded and substituted into the following equation to yield the
concentration of free metal remaining in solution:
[M]free, M = Kd( F – F0)/ (Fmax – F)

[38],

(Equation 2.2)

where Kd represents the binding affinity of ProCA-31 to gadolinium (previously determined to
be 1.04 x 10-11), F represents the maximum fluorescence intensity of the peak corresponding to
the ProCA-31-Gd3+ complex and dye, F0 represents the EGTA treated sample that returns the
signal to baseline, and Fmax represents the maximum intensity of the peak corresponding to the
ProCA-31-Gd3+ complex and dye saturated with gadolinium [38]. The incubation time yielding
the lowest concentration of free metal was chosen to be the standard time allowed for metal
equilibration of future relaxivity samples.
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2.6. Relaxometry
The T1 and T2 values of protein and/or metal samples were measured using a Bruker
Minispec combined with an mq60 NMR Analyzer at 37ºC, a temperature monitored and
controlled by a digitally operated water bath, at 60MHz or 1.5 Tesla. Verification of the
temperature was also obtained manually using an alcohol thermometer. The samples to be
measured consisted of either a 10mM Tris/HCl chelex pH 7.4 (low salt) or 10mM Tris/HCl
100mM NaCl chelex pH 7.4 (high salt) buffering system, in which varying concentrations (10 to
50µM) of a desired protein was suspended. An amount of metal, either calcium or gadolinium,
was added in a one to one or one to two concentration relative to the protein concentration to
observe changes in relaxivity. Additionally, experiments were conducted using a fixed
concentration of gadolinium and varying ProCA-3 concentration to determine whether the
binding of the metal to ProCA-3 is one to one or one to two. The average relaxivity from this
experiment is taken as the average of the relaxivity of ratios located in the plateau portion of the
curve. The following equation was used to calculate the relaxivity with respect to each relaxation
time:
1/T1,2 = (1/T1,2 sample – 1/T1,2 buffer)/ [Gd3+] [10].

(Equation 2.3)

Using a Bruker Minispec application program, basic instrumental parameters were checked
using a mineral oil sample. Following a daily check of the instrumental parameters (to be
performed once per day of use), the instrumental gain was tuned using a buffer only sample. The
gain value obtained for the T2 program was used for the T1 program. Each sample was measured
in the following fashion: T2 first and then T1, with a 5 minute warming time for each sample at
37ºC prior to measurement. Following collection of data, the percent of T1 and T2 signals were
plotted in Kaleidagraph 3.5 as a function of time to chart the change in relaxation signal over
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time. For fixed ratio experiments, the data obtained was plotted in Kaleidagraph 3.5 as protein
concentration vs. 1/T1 or 1/T2 to yield R1 and R2 values. For varying ratio experiments at a
fixed concentration of gadolinium, the data obtained was plotted in Kaleidagraph 3.5 as protein
concentration vs. 1/T1 or 1/T2, yielding averaged R1 and R2 values from the plateau portion of
the curve and allowing one to infer the binding mode of the contrast agent to gadolinium: 1 to 1
or 1 to 2. By nature of design, we anticipate that the binding mode is 1 to 2.
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3. EXPRESSION AND PURIFICATION RESULTS
3.1. Background
To obtain a large quantity of contrast agent for animal model studies and future clinical
trials, it is extremely important to have a time-effective, cost conscientious, well established
protocol for achieving a high yield of purified Class ProCA-3 agents. In this chapter, the
expression results will reveal that each designed contrast agent of this class was successfully
overexpressed using the aforementioned expression protocol in the chapter 2. Following
improvements and modifications made to the established protocol for parvalbumin expression
and purification, it will be later shown that members of Class ProCA-3 can be effectively
isolated and purified. Studies were performed to improve the product yield by overcoming the
limitations associated with the isolation of a tagless protein from nucleic acids coexisting in the
supernatant following cell lysis.
3.2. Expression Results
As discussed in section 2.2.1, pilot expression procedures were implemented to analyze the
cell strain and IPTG concentration optimal for overexpression of protein. Figure 3.1 indicates
that the cells of all tested strains grew fairly well in LB media. Here, it’s evident that BL21(De3) pLysS and Tuner (De3) pLac I cell strains grew best prior to overnight incubation. After
overnight growth, there seems to be no considerable difference in cellular growth amongst the
different strains. Additionally, the varied concentrations of IPTG appear to have little to no effect
on cell growth for all tested cell strains.
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Figure 3.1. Cellular growth curve of pilot expression results.
Unlike previous expression experiments, SDS-PAGE analysis reveals that the BL-21
(De3) pLys strain did not overexpress the protein very well (Figure 3.2). The Rosetta pLysS
expressed ProCA-30 at an intermediate level of expression compared to the enhanced
overexpression in the Tuner pLacI strain. There appears to be little preference for overexpression
between the two varying IPTG concentrations.
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Figure 3.2. SDS-PAGE gel pilot expression results.
Taking into account the previous expression experiments of ProCA-30, the BL-21 pLys
(De3) strain at 1mM IPTG allows for expression exclusively in the supernatant. The Tuner strain
allowed for expression both in the supernatant and inclusion bodies (Figure 3.3). This condition
is not favorable as the protein from each location will have to be purified separately. Protein
expressed in the supernatant will be in a soluble form and likely folded properly. The protein
expressed in the inclusion bodies will likely not be properly folded. The Rosetta pLys strain did
not yield any protein in the supernatant. It was decided to continue expression in the BL-21 pLys
(De3) strain to simplify purification of the tagless protein.
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Figure 3.3. SDS-PAGE gel results following pilot expression cell fractionation.
ProCA-30
Following successful transformation of pET-22b(+)-ProCA-30 into BL-21 pLys cells, the
procedures implemented for expression were identical to those described in the materials and
methods section. According to the increasing optical density of cell culture, the cloned cells
containing the gene encoding for ProCA-30 grew very well (Figure 3.4A). This observation was
further evidenced by the increasingly “cloudy” appearance of the cell culture as incubation time
increased. SDS-PAGE gel analysis indicates that there was little desired ProCA-30 expressed
prior to induction with IPTG (Figure 3.4B). Following induction, it is clear that the heavier
bands on the gel for samples after IPTG addition as compared to the one before induction
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indicate that not only did the cells receive the signal to begin expressing the variant in high yield
but a significant amount of protein was overexpressed. There was only a slight difference in the
density of bands on the gel before and after overnight growth following induction. This indicates
that overnight growth at a reduced temperature did little to significantly enhance the
overexpression of ProCA-30. However, this effect observed is not sufficient to modify the
procedure and eliminate overnight growth. Further expression of ProCA-30 and its variants are
necessary to make such a conclusive decision.

Figure 3.4. ProCA-30 Overexpression. (A) E. Coli ProCA-30 cellular growth curve. (B) ProCA30 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media.
ProCA-31
Following successful transformation gene of pET-22b(+)-ProCA-31 into BL-21 pLys
cells, the contrast agent was expressed according to the methods described in the materials and
methods section. According to the increasing optical density of cell culture, the cloned cells
containing the gene encoding for ProCA-31 grew very well (Figure 3.5A). Like the expression of
ProCA-30, this observation was further evidenced by the increasingly “cloudy” appearance of
the cell culture as incubation time increased. It appears that a small amount of ProCA-31 was
expressed prior to induction. To provide an explanation for the faint bands in lanes 2 and 3 of the
SDS-PAGE gel, it is important to note that the top closing the eppendorf tubes of samples from 1
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and 3 hours after induction were not secure (Figure 3.5B). Therefore, these samples were diluted
during the boiling step prior to running SDS-PAGE. Following induction, the heavier bands on
the gel for 5 hr and overnight samples indicate that a significant amount of protein was
overexpressed. There was little difference in the density of bands on the gel before and after
overnight growth following induction. This indicates that overnight growth at a reduced
temperature did little to significantly enhance the overexpression of ProCA-30. Still, this effect
observed is not sufficient to modify the procedure and eliminate overnight growth. Further
expression of ProCA-31 and the remaining members of Class ProCA-3 are necessary to make
such a conclusive decision.

Figure 3.5. ProCA-31 Overexpression. (A) E. Coli ProCA-31cellular growth curve. (B) ProCA31 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media.
ProCA-32
pET-22b(+)-ProCA-32 was transformed into BL-21 pLys cells and expressed according
to the procedures described in the materials and methods section. According to the increasing
optical density of cell culture, the cloned cells containing the gene encoding for ProCA-32 grew
very well (Figure 3.6A). SDS-PAGE gel analysis indicates that there was a fair amount of
protein expressed prior to induction with IPTG (Figure 3.6B). There is little difference between 1
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and 3 hour induced states. Furthermore, provided an equal amount of each sample was loaded
onto the gel, overnight condition after induction yields slightly more desired protein when
compared to 5 hours following induction. Overall, it is clear that a significant amount of protein
was overexpressed during this expression experiment.

Figure 3.6. ProCA-32 Overexpression. (A) E. Coli ProCA-32 cellular growth curve. (B) ProCA32 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media.
ProCA-33
pET-22b(+)-ProCA-33 was successfully transformed into BL-21 pLys cells. The
procedures for expression were identical to those described in the materials and methods section.
According to the increasing optical density of cell culture and the increasingly “cloudy”
appearance of the cell culture as incubation time increased, the cloned cells containing the gene
encoding for ProCA-33 grew very well (Figure 3.7A). Although SDS-PAGE gel analysis
indicates that there was a small amount of protein expressed prior to induction, the increased
density of bands on the gel for samples following induction indicate that a significant amount of
protein was overexpressed (Figure 3.7B). Like ProCA-32 overexpression, there was a notable
difference in the density of bands on the gel for 5 hour and overnight growth after induction.
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This indicates that overnight growth at a reduced temperature enhances the overexpression of
ProCA-33.

Figure 3.7. ProCA-33 Overexpression. (A) E. Coli ProCA-33 cellular growth curve. (B) ProCA33 overexpression in E. Coli BL-21 pLys (DE3) cells in LB media.
3.3. Optimizing the Purification Protocol
3.3.1. Old Purification Method and Its Limitations
The original purification protocol was identical to the current protocol with the following
exceptions: a 1% streptomycin sulfate concentration was used, there was no dialysis step
introduced prior to injection of the supernatant onto the Q-column, the pH of the FPLC buffers
was 7.4, the program for FPLC separation was not optimized, and a second FPLC run using
another set of buffers introducing calcium into the system was introduced (Figure 3.8).
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Old Method of Purification:
1.33µM
benzonuclease with
its cofactor MgCl2

Sonicator (or Fr. Press)

1% strep.

Centrifugation at
17K, 4°C, 30
minutes

Six 30 second increments
with 1 minute on ice
between each subjection
(French press completed for
a total of 3 trials)

Supernatant
was collected
and cell pellet
discarded

Allow solution to
incubate at 4ºC
overnight

Add streptomycin
sulfate and shake
overnight at 4ºC
Centrifugation at
17K, 4°C, 30
minutes

Condition 1

Condition 2

Buffer A‐ 10mM
Tris/HCl, 3mM
EDTA, pH 7.4

Buffer A‐ 10mM
Tris/HCl, 3mM CaCl2,
pH 7.4

Buffer B‐ 10mM
Tris/HCl, 3mM
EDTA, 1M NaCl, pH
7.4

Buffer B‐ 10mM
Tris/HCl, 3mM
CaCl2,, 1M NaCl, pH
7.4

Supernatant was
collected and cell pellet
discarded

Figure 3.8. Original purification protocol prior to modifications.
For simplification purposes, the expression gels pertaining to the purification results
using the older protocol are not depicted. However, it’s important to note that the expression
results from these experiments were comparable to those mentioned in the previous section.
The results for each ProCA-3 member purified according to the original purification methods
described in Figure 3.8 are as follows:
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Figure 3.9. ProCA-30 Old Purification Protocol Results. (A) SDS-PAGE from purification. (B)
FPLC Condition 1 in the absence of calcium. (C) Left to Right: FPLC Condition 2 results in the
presence of calcium and UV-Spectrum results of collected fractions.
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Figure 3.10. ProCA-31 Old Purification Protocol Results. (A) SDS-PAGE from purification and
FPLC Condition 1 in the absence of calcium. (B) FPLC Condition 2 results in the presence of
calcium. (C) UV-Spectrum results of collected fractions.
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Figure 3.11. ProCA-32 Old Purification Protocol Results. (A) SDS-PAGE from purification. (B)
FPLC Condition 1 in the absence of calcium. (C) FPLC Condition 2 results in the presence of
calcium. (D) UV-Spectrum results of collected fractions.
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Figure 3.12. ProCA-33 Old Purification Protocol Results. (A) SDS-PAGE from purification. (B)
FPLC Condition 1 in the absence of calcium. (C) FPLC Condition 2 results in the presence of
calcium. (D) UV-Spectrum results of collected fractions.
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There are several limitations to the old purification methods used to extract Class ProCA-3
agents from an E.Coli cell pellet: Q-column overloading, high concentration of nucleic acids
present in supernatant, inability to separate protein from nucleic acid due to inefficient FPLC salt
gradient method, and loss of protein during the second FPLC condition when calcium is
introduced into the system. As one can infer from Figures 3.9 -3.12, the purification gels reveal
that the predominant protein injected onto the Q-column is the desired overexpressed variant.
Prior to FPLC injection, there is little undesired protein present in the supernatant. At this stage,
it was assumed that the predominant biomolecules present in the supernatant were the desired
contrast agent and nucleic acids (verified by UV-spectrum). However, FPLC condition 1 (no
calcium) and condition 2 (in presence of calcium) chromatograms clearly indicate that the
proteins are not binding to the column well, eluting from the column before the salt gradient is
introduced for both conditions 1 and 2 FPLC injections. This is also evidenced by the bands
pertaining to the collected fractions at approximately 12 kDa on the SDS Page gels. Because
nucleic acids are negatively charged in solution at pH 7.4, they have a higher affinity for anionic
Q-column than the contrast agents. It’s possible that the column efficiency was reduced due to
the inability of 1% streptomycin sulfate, supplemented with heat, to precipitate the substantial
concentration of nucleic acids that coexist with the desired contrast agent in the supernatant prior
to FPLC injection. Thus, the column became saturated with the high concentration of nucleic
acids remaining in the supernatant and reduced the column’s capacity to bind the contrast agents.
Additionally, it’s evident that the FPLC salt gradient may not be optimal for separation. It
increases sharply to 70% NaCl and steadily to 100% NaCl. Because the members of Class
ProCA-3 bind calcium very strongly, on the order of 10-9M, it is very difficult to achieve the
apo-form of the variants for future analysis. Therefore, other than the consequential loss of
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protein associated with an increase in subsequent purification steps, the second FPLC condition
introducing calcium into the purification system is not ideal. Thus, modifications to this protocol
will be devoted to increasing column capacity by cleaning the Q-column more efficiently with a
combination of ethanol, 1M NaCl, deionized water, and Buffer A prior to injection and by
decreasing the amount of nucleic acids coexisting in the supernatant. Furthermore, diluting the
highly concentrated supernatant before FPLC injection and modifying the salt gradient of the
FPLC program to allow for effective isolation of the desired contrast agent will significantly
improve the purification yield.
3.3.2. Streptomycin Variation to Reduce Nucleic Acid Concentration in the Supernatant
The members of Class ProCA-3 agents are soluble variants that typically lie in the
supernatant following cell lysis. It is well known that nucleic acids are also very soluble and lie
in the supernatant. Because both nucleic acids and the variants of this class are negatively
charged in solution, the primary goal is to isolate a pure, functional form of each contrast agent
devoid of any “contamination,” including nucleic acids. More specifically, it was thought that
the presence of a high concentration of similarly negatively charged nucleic acids in the
supernatant injected onto the Q-column could possibly saturate the positively charged column
and decrease its efficiency by interfering with the proteins’ optimal binding. For the purposes of
this thesis, three variants of ProCA-30 were arbitrarily chosen reducing the concentration of
nucleic acids in the supernatant: PV-S56D, PV-E60D, and PV-G99D.
Prior to streptomycin treatment for purification, a 1mL sample of each mutant was treated
with 1%, 3%, 5%, and 10% streptomycin sulfate to observe which concentration was optimal for
the removal of nucleic acids and other proteins not thermally stable at high temperatures. The
effects of concentrations of streptomycin sulfate above 10% were not investigated in efforts to
55

reduce the amount of “impurities” introduced into the purification schemes. Following treatment
with streptomycin sulfate, the samples were incubated overnight at 4˚C per the purification
protocol, and agarose and SDS gels were run on the samples the following day. Because SDS gel
electrophoresis requires that samples be boiled with a loading buffer before loading onto the gel,
the SDS-PAGE results are post boiling while the agarose gel samples were taken and run before
boiling. The intensity of the agarose gel bands should be the same for each condition. However,
the migration distance will vary with different streptomycin sulfate concentrations based upon
how efficiently streptomycin sulfate binds the nucleic acids in the sample. SDS-PAGE results
allow one to infer the degree of precipitation of thermally unstable proteins present in each
sample. Using these tools, the optimal concentration of streptomycin sulfate used during the
purification process can be approximated.
PV-S56D and PV-E60D were overexpressed again according to previous expression
protocols and were very successful. Once streptomycin sulfate was added, samples of PV-S56D
and PV-E60D were analyzed (Figure 3.13).
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Figure 3.13. Varying Strep. Treatment Conditions to S56D and E60D. (A) PV-S56D results. (B)
PV-E60D results.
Agarose gel results of PV-S56D reveal that the treatment of the supernatant before
benzonuclease (BB) versus after the treatment (AB) yields a slight increase in fragmentation of
the nucleic acids as evidenced by the more migrated band in the AB lane (Figure 3.13A). SDSPAGE analysis of these samples yields slightly less protein following the addition of
benzonuclease because the boiling of samples required for SDS gel analysis may have facilitated
the precipitation of thermally unstable proteins. It is important to note here that the striated bands
on the SDS gel for 5% and 10% streptomycin treatment are typical results associated with SDSstreptomycin sulfate experiments due to heat-facilitated precipitation of sample components.
This pattern likely occurs at higher concentrations of streptomycin sulfate because more proteins
are precipitated, making it more difficult for the bands to pull down during electrophoresis. To
allow for more conclusions to be drawn from SDS gel analysis, the supernatant isolated from
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centrifugation of these samples should have been run on the gel to avoid the negative effects
associated with significant protein precipitation during SDS-PAGE.
It appears that 1% streptomycin sulfate is optimal for PV-S56D nucleic acid precipitation
because its band has a higher molecular weight than that of the other tested streptomycin sulfate
concentrations (streptomycin binds to DNA yielding a higher molecular weight) shown in the
agarose gel and it appears to have a reduced amount of undesired proteins (SDS gel) present in
the supernatant following heat. Furthermore, the 1% cell pellet isolated from centrifuging the 1%
streptomycin sulfate sample contains a comparable amount of nucleic acids, though at a smaller
molecular weight. Due to a flaw in experimental design, the concentration of nucleic acids in the
cell pellets from other tested streptomycin sulfate concentrations were not run on the gel and
thus cannot be compared to the 1% cell pellet. This will be later addressed with PV-G99D
experiments. Because the SDS gel results are not conclusive this experiment was repeated with a
different variant of ProCA-30, PV-E60D.
Like PV-S56D, the treatment of PV-E60D supernatant before benzonuclease (BB) versus
after the treatment (AB) yields a slight increase in fragmentation of the nucleic acids as
evidenced by the more migrated band in the AB lane (Figure 3.13B). It is unclear why SDSPAGE analysis of these samples yields slightly less protein following the addition of
benzonuclease. Furthermore, it is unclear why the amount of nucleic acid for each streptomycin
concentration sample differs. While nucleic acid concentration appears to be inconsistent for 5%
and 10%, 1% and 3% appear to maintain comparable concentrations of nucleic acids. This may
be due to human sample loading error. Nevertheless, based solely on the reduced distance of
band migration for agarose gel electrophoresis and the reduced amount of undesired proteins
(SDS gel) present in the supernatant following heat, it appears that 3% streptomycin sulfate is
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optimal for nucleic acid removal. The absence of “band striations” at 10% streptomycin sulfate
for this variant compared to that of PV-S56D may be related to the heterogeneous nature of the
samples run on the SDS gel.
PV-G99D was overexpressed very well and subjected to the varying streptomycin sulfate
concentration experiment (Figure 3.14). Using a similar method of analysis as achieved with PVS56D and PV-E60D but implementing the boiling and centrifugation steps prior to gel analysis,
it appears that 5% streptomycin sulfate is optimal for DNA precipitation from the supernatant of
G99D (Figure 3.14). The reduction of nucleic acids present in the supernatant before and after
heating and centrifugation is most significant at 5% streptomycin sulfate (lanes 8 and 9).
Furthermore, the 5% cell pellet contains the highest concentration of nucleic acid isolated from
the supernatant following heat and centrifugation. It’s important to note that heat significantly
facilitates the precipitation of nucleic acids removed by precipitation.
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Figure 3.14. PV-G99D varying streptomycin sulfate treatment agarose gel results. (A)
Streptomycin screening for optimal conditions. (B) Changes in nucleic acid concentration at 5%
streptomycin sulfate.
Overall, it appears that the streptomycin sulfate precipitation method is effective at
reducing the concentration of nucleic acids in the supernatant. While the data from PV-S56D and
PV-E60D insinuates that 1-3% streptomycin sulfate is optimal for binding to nucleic acids in the
supernatant and facilitating their precipitation, it does not incorporate the use of heat and
centrifugation into agarose gel analysis, which has shown to significantly decrease the
concentration of nucleic acids in the experiment using PV-G99D. From the G99D experiment, it
was found that 5% streptomycin sulfate concentration is optimal for nucleic acid precipitation
from the protein supernatant following overnight cleavage of nucleic acids with benzonuclease.
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This is evidenced by the reduced concentration of nucleic acids present in the supernatant
following heating and centrifugation and the increase of nucleic acids present in the 5% cell
pellet conditions. Therefore, the purification protocol was modified to use 5% streptomycin
sulfate process for nucleic acid precipitation.
3.3.3. Modified FPLC Program
Previous FPLC experimental conditions allowed for a second FPLC run during which
Buffers A and B contained 3mM Ca instead of EDTA. However, this step was eliminated to
reduce the number of steps required to isolate the apo-form of the proteins for metal analysis via
circular dichroism, relaxivity, and fluorescence. It is well known that the native form of ProCA30 binds calcium with a high affinity and it is difficult and time-consuming to remove the metal
ions at such a high concentration of calcium previously used. Additionally, with each successive
step of the purification process, there are consequential subsequent losses of protein. Thus, the
elimination of this step along with an optimal salt gradient of separation, may allow for isolation
of a higher quantity of protein.
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Figure 3.15. Typical FPLC chromatogram of ProCA-3 agents by Q-column separation and the
UV absorbance of each fraction.
Figure 3.15 depicts the characteristic chromatogram and UV absorbance spectra resulting
from Q-column FPLC separation of ProCA-3 agents cell lysate. Each labeled peak directly
corresponds to the numbers used to label the lanes on both the SDS-PAGE gel and the agarose
gel. Here, the FPLC gradient was modified from a sharp increase to 70% NaCl and steady
increase to 100% NaCl (old protocol) to final program specifications of column washing with
15mL of Buffer A, a steady increase to 25% NaCl and then holding that concentration for three
column volumes (15mL) before a sharp increase to 100% NaCl to elute any bound proteins or
nucleic acids to the Q-column. This program was implemented on ProCA-30, ProCA-31,
ProCA-32, and ProCA-33 (Figures 3.17-3.20). As one can infer from the broad peak at 260nm of
the UV-spectrum corresponding to peak 1 and the absence of a band on the SDS-PAGE gel, peak
1 is likely smaller fragments of nucleic acids and to a lesser degree of undesired protein that did
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not bind to the column. Because the concentration of fragmented nucleic acids was low, it did
not show on the agarose gel. Peak 2 is the isolated variant and likely corresponds to the apo-form
of N-formyl methionine-cleaved ProCA-3. This is confirmed by SDS-PAGE gel, agarose gel,
and mass spectrometry data (Figure 3.15, Figure 3.16).

Figure 3.16. Mass spectrometry results of peaks 2 and 3 from the modified purification protocol.
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Peaks 3, 4, and 5 are believed to be the holo-forms of methionine-cleaved ProCA-3 agents. SDSPAGE gel, agarose gel, and mass spectrometry data confirms the speculations of peak 3
identification (Figure 3.15, Figure 3.16). Summarizing the results, the modified FPLC program
yields a significant improvement in the overall yield of protein to a high degree of purity
compared to the old methodology (Table 3.1).

Figure 3.17. ProCA-30 Purification. (A) SDS-Page results of purification process. (B) FPLC
chromatogram depicting isolation of target variant.

64

Figure 3.18. ProCA-31 Purification. (A) SDS-Page results of purification process. (B) FPLC
chromatogram depicting isolation of target variant. (C) Relevant SDS Page results from FPLC
separation.
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Figure 3.19. ProCA-32 Purification. (A) SDS-Page results of purification process. (B) FPLC
chromatogram depicting isolation of target variant and relevant SDS Page results from FPLC
separation.
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Figure 3.20. ProCA-33 Purification. (A) SDS-Page results of purification process. (B) FPLC
chromatogram depicting isolation of target variant and relevant SDS Page results from FPLC
separation.
3.4. Final Yield
Summarizing the aforementioned results of his chapter, the unrevised purification
protocol closely resembles that of the current protocol. However, there were a few minor
changes made that have drastically increased the purification yield. Incorporating the use of an
optimal streptomycin sulfate concentration and modifying the FPLC salt gradient for separation,
the yields of all members of Class ProCA-3 agents have increased nearly four to six times
compared to the old methods with the exception of ProCA-33. Figures 3.21 and 3.22 further
confirm the purity of contrast agent isolated. The UV spectra obtained are closely related to that
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of the published expected spectra (see section 2.3). The yield of ProCA-33 was 39.41 mg and did
not significantly increase compared to the implementation of the old purification protocol due to
the inefficiency of the contrast agent binding to the Q-column. This is evidenced by the low
resolution observed between the first two peaks in the FPLC chromatogram (Figure 3.15). This
inefficacy is related to insufficient cleaning of the column and was due to human error.

Figure 3.21. Maldi-TOF results confirming identity and purity of isolated members of Class
ProCA-3 agents.

Figure 3.22. Final UV absorbance spectra of class ProCA-3 agents.

Table 3.1. ProCA-3 Purification Yields
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ProCA-3

ProCA-30

ProCA-31

ProCA-32

ProCA-33

37.50 mg
32.60 mg
41.50 mg
Old Yield from 31.70 mg
2L LB media
76.16 mg
60.21 mg
39.41 mg*
New Yield from 109.12 mg
1L LB media
*Due to human error, there was no significant increase in yield due to loss of protein during the
FPLC injection stage.
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4. CONFORMATIONAL ANALYSIS AND METAL STUDIES
4.1. Background
It is of crucial importance that the structural integrity of the designed protein-based
contrast agents of Class ProCA-3 maintains the native structure of parvalbumin, the scaffold
protein. Maintenance of the characteristic alpha-helical structure allows one to draw the
conclusion that the introduction of mutations into the skeletal structure does not significantly
alter or perturb the proteins secondary structure, providing insight into their relative stabilities.
Figure 4.1 depicts the published Far-UV spectrum of parvalbumin in the presence and absence of
calcium.

Figure 4.1.Published Far-UV spectrum of wildtype parvalbumin; Dashed line, metal-free form;
solid line, Ca2+ loaded form [39].
Using circular dichroism to measure the Far-UV region absorptions, one is able to detect
changes in secondary structure alone. It is important to note here that this technique does not
allow one to draw conclusions about the intrinsic stability of the gadolinium binding site as a
result of the introduced mutations in ProCA-31, ProCA-32, or ProCA-33. Furthermore,
measuring the optical absorptions in the Far-UV CD region does not provide any indication of
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potential changes in the globular or tertiary structure of the designed agents. To detect tertiary
structural changes of the agents, the Near-UV spectrum, instead of the Far-UV region, must be
examined using circular dichroism. However, for the purposes of this thesis, only the Far-UV
CD region was observed.
Not only is the maintenance of the secondary structure following the introduction of
mutations important, but it is also of crucial importance to investigate the effects of increasing
concentrations of physiological metal ions and high salt on the stability of the structure. For the
purposes of this discussion, the effects of magnesium, calcium, gadolinium, and terbium will be
examined.
4.2. Magnesium-Induced Structural Effects
Magnesium is a divalent metal that plays a major role in a number of biological
processes. Under normal physiological conditions, the extracellular concentration of magnesium
is 1-2mM. Native parvalbumin acts as a cytosolic buffering protein, respectively binding both
calcium and magnesium, on the orders of 10-9M and 10-6M [25]. Therefore, at a fixed 6µM
concentration of protein, the spectral changes associated with the addition of magnesium
chloride to each contrast agent of Class ProCA-3 was observed at a 1:1 protein to Mg2+
concentration ratio, 1:2 protein to Mg2+ concentration ratio, 1mM Mg2+ , and an excessive
amount of 5mM Mg2+. The metal-induced structural changes were observed under both low and
high salt conditions. A major assumption drawn for these experiments is that the background
metals and EDTA from purification present in the buffer system are below the micromolar range.
However, this must be further verified. Nevertheless, some conclusions can be drawn.
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4.2.1. ProCA-30
ProCA-30 secondary structure changes under varying concentrations of magnesium were
observed. At low salt concentrations, the protein maintains its native α-helical character with
slight decreases in its helicity for the holo forms (Figure 4.2). Under high salt conditions, the
reverse is true up to 1mM additional magnesium. At 5mM calcium, the helicity decreases. Here,
it’s safe to assume that the presence of high salt helps to stabilize ProCA-30 up to 1mM
magnesium. As will be later explained, more pronounced spectral differences are primarily seen
between the low and high salt forms of the protein in the presence of calcium.

Figure 4.2. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to magnesium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 100mM NaCl was used.
4.2.2. ProCA-31
ProCA-31 yields characteristic alpha-helix wavelength absorbencies at 209 nm and 222
nm in the absence of additional added metals and in the presence of increasing concentration of
magnesium under both low and high salt conditions (Figure 4.3). Thus the introduction of a
F103W mutation does not significantly alter the secondary structure of the protein. For varying
72

ratios of magnesium, like ProCA-30, ProCA-31 decreases in helical character as the
concentration of added magnesium increases under low salt conditions. The same can be said for
high salt conditions, though more pronounced spectral differences were noted. Here, the
presence of high salt has little effect on the stability of ProCA-31 in the presence of magnesium.

Figure 4.3. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to magnesium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.2.3. ProCA-32
Under the subjection to circularly polarized light, the Far-UV CD spectrum of 6µM
ProCA-32 yields characteristic alpha-helix wavelength absorbencies at 209 nm and 222 nm in
the presence of increasing concentrations of magnesium (Figure 4.4). This indicates that the
mutation does not significantly alter the secondary structure of the protein. The helical content of
the protein appears to slightly increase in the presence of magnesium under low salt conditions,
implying enhanced stability. There are little notable spectral differences with increasing
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concentration of magnesium under high salt conditions, indicating that ProCA-32 is fairly stable
under comparable extracellular conditions.

Figure 4.4. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to magnesium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.2.4. ProCA-33
It is unclear whether the introduction of an aspartic acid in place of glutamic acid at
position 60 located in the CD site and a tryptophan in lieu of phenylalanine at position 103
located just outside of the EF site will significantly alter the secondary structure of the native
skeletal design of the contrast agent. Furthermore, we are not certain of the metal-induced
structural effects of this contrast agent. For varying concentrations of magnesium in a low salt
buffer, ProCA-33 helical content is enhanced with increasing concentrations of magnesium
(Figure 4.5A). With the exception of a slight decrease in helicity at 5mM magnesium, the helical
content under high salt conditions remains fairly consistent, indicating that high salt plays little
role in secondary structure destabilization of ProCA-33 in the presence of magnesium (Figure
4.5B).
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Figure 4.5. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to magnesium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.3. Calcium-Induced Structural Effects
Calcium ions are one of the most abundant minerals in the human body and is essential
for living organisms, particularly in cell physiology [40-41]. Though its concentration is 104 to
106-fold less than that of magnesium and potassium intracellulary, respectively, calcium is not
only “an essential structural component in the biomineralization of teeth, bones, and shells but
also a ‘second messenger’ that controls numerous cellular processes such cell division and
growth, secretion, ion transport, and muscle contraction through calcium-induced conformational
change” [28]. More specifically, calcium-binding proteins with varying affinities for this metal
mediate and regulate both extracellular and intracellular calcium-dependent functions [28].
Because their metal selectivity over other metal ions is closely related to many physiological
processes and diseases, understanding the key factors in their selectivity and conformational
change allows for a more in depth analysis of calcium signaling [28, 42].
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4.3.1. ProCA-30
Pronounced spectral differences are primarily seen between the low and high salt forms
of the protein in the presence of calcium (Figure 4.6). Under low salt conditions, ProCA-30 is
destabilized as the concentration of calcium increases. Under high salt conditions, there are little
notable differences with increasing concentrations of calcium with the exception of a decrease in
helicity at 5mM calcium. Here, one can draw the conclusion that the presence of salt does little
to perturb the structure up to 1mM calcium.

Figure 4.6. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to calcium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.3.2. ProCA-31
Because the alpha-helical structure is maintained, one can assume that the introduction of
a F103W mutation just outside of the EF binding site does not significantly perturb the
secondary structure of the protein (Figure 4.7). For varying ratios of calcium, more pronounced
spectral changes between the different ratios of magnesium predominately occur under low salt
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conditions (Figure 4.7). Under high salt conditions, there are little notable changes in the helical
content, indicating that the ProCA-31 is stable under applicable in vivo salt concentrations.

Figure 4.7. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to calcium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.3.3. ProCA-32
The alpha-helical fold of ProCA-32 is maintained with introduction of a S56D mutation
in the CD site of wildtype parvalbumin, indicating that the mutation does not significantly alter
the secondary structure of the protein (Figure 4.8). In the presence of varying metal ratios in the
absence of EGTA treatment at low and high salt concentrations, the protein maintains its native
α-helical character (Figure 4.8). For varying ratios of calcium under both low and high salt
conditions, ProCA-32 increases in helical character for all ratios and concentrations of metal
added. Thus, ProCA-32 is a stable variant and the presence of high salt does little to destabilize
the secondary structure.
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Figure 4.8. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to calcium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.3.4. ProCA-33
The alpha-helical fold of ProCA-33 is maintained with introduction of an E60D mutation
in the CD site of wildtype parvalbumin, indicating that the mutation does not significantly alter
the secondary structure of the protein. In the presence of varying metal ratios in the absence of
EGTA treatment at low and high salt concentrations, the protein maintains its native α-helical
character (Figure 4.9). For varying ratios of calcium, dominant spectral changes are more visible
under low salt conditions. The helical content increases for all concentrations of added calcium
under low salt while there are little to no spectral changes under high salt conditions. Like the
aforementioned members of Class ProCA-3 in the presence of calcium, the presence of high salt
does little to destabilize the secondary structure of the designed contrast agents.

78

Figure 4.9. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to calcium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.4. Gadolinium-Induced Structural Effects
Gadolinium is a paramagnetic metal whose local magnetic field perturbs the relaxation of
water protons located on its surface. Once again, the members of Class ProCA-3 are expected to
bind gadolinium in a 1 to 2 fashion. Here, we want to observe how the binding of gadolinium
affects the secondary structure of the protein.
4.4.1. ProCA-30
Under both low and high salt conditions, the helical content of ProCA-30 appears to
decrease for all added concentrations of gadolinium (Figure 4.10). This indicates that gadolinium
is able to competitively displace “background metals” from the CD and EF binding sites, even at
low concentrations of 6µM (1 to 1) and 12µM (1 to 2) gadolinium. However, this also indicates
that gadolinium slightly destabilizes the secondary structure of ProCA-30 under both low and
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high salt conditions. The presence of a high concentration of salt does little to perturb the
structural changes associated with gadolinium-binding.

Figure 4.10. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to gadolinium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.4.2. ProCA-31
Because the native alpha-helical structure is maintained, it appears that the F103W
mutation does not significantly alter the secondary structure of ProCA-31. For various added
concentrations of gadolinium, ProCA-31 is destabilized because the helical character decreases
for all ratios and concentrations (Figure 4.11). More pronounced spectral differences are
associated with low levels of salt. There were only minor decreases in the helical content as
increasing concentrations of gadolinium was added under high salt conditions. Thus, one can
assert that the presence of high salt plays a nominal role in stabilizing the structure compared to
low salt conditions. Nevertheless, as one can infer from Figure 4.11, the native structure of the
ProCA-31 is maintained in the presence of gadolinium.
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Figure 4.11. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to gadolinium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.4.3. ProCA-32
The alpha-helical fold of ProCA-32 is maintained with introduction of a S56D mutation
in the CD site of wildtype parvalbumin, indicating that the mutation does not significantly alter
the secondary structure of the protein (Figure 4.12). For varying ratios of gadolinium, the helical
character increases for almost all ratios and concentrations of added metal under both low and
high salt conditions (Figure 4.12). Slightly less spectral differences were noted under high salt
conditions, indicating that the presence of 100mM NaCl marginally enhances ProCA-32
stability. Nevertheless, the ProCA-32 alpha-helical content retains the native structure in the
presence of gadolinium.
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Figure 4.12. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to gadolinium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.4.4. ProCA-33
The alpha-helical fold of ProCA-33 is maintained with introduction of an E60D mutation
in the CD site of wildtype parvalbumin (Figure 4.13). In the presence of varying gadolinium
ratios in the absence of EGTA treatment at low and high salt concentrations, the protein
maintains its native α-helical character (Figure 4.13). For varying ratios of gadolinium, the
helical content increases for all ratios and concentrations under low salt conditions. Minimal
spectral changes were observed under high salt conditions indicating that the presence of salt
ions help to stabilize the secondary structure of ProCA-33.
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Figure 4.13. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to gadolinium
ratios. (A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH
7.4 (100 mM NaCl) was used.
4.5. Terbium-Induced Structural Effects
Terbium is a trivalent metal ion used in fluorescent spectroscopy studies to probe the
intrinsic properties of metal binding sites within biomolecules. Studies of this sort can provide
information concerning the stability of the metal binding site and also contribute to quantifying
the binding affinity of a biomolecule to a metal. Although these experiments were not discussed
in this thesis, they will be performed in the near future. Thus, it was of importance to examine
the secondary structural changes associated with increasing concentration of this metal.
4.5.1. ProCA-30
ProCA-30 maintains an alpha-helical structure like that of wildtype parvalbumin. More
specifically, the structure is maintained with increasing concentrations of terbium (Figure 4.14).
The spectral differences associated with the low salt spectrum were slightly greater than that of
the high salt spectrum. Terbium appears to slightly destabilize the secondary structure of ProCA-
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30 under both low and to a nearly negligible degree of high salt conditions. Nevertheless, the
native structure is maintained as the concentration of terbium increases.

Figure 4.14. Far UV spectra of 6 µM ProCA-30 in the presence varying protein to terbium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.5.2. ProCA-31
As mentioned previously, the effects of F103W mutation on the fold of the protein are
minor (Figure 4.15). For increasing ratios of terbium, the helical character decreases for all ratios
and concentrations. Like ProCA-30, there are nominal spectral differences associated with
increasing concentrations of terbium under high salt conditions compared to low salt conditions.
Although the helicity is destabilized under both conditions, high salt helps to counter this
destabilization. Still, one can conclude that the secondary structure is maintained in the presence
of terbium at the tested concentrations.
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Figure 4.15. Far UV spectra of 6 µM ProCA-31 in the presence varying protein to terbium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.5.3. ProCA-32
Once again, the alpha-helical fold of ProCA-32 is maintained with introduction of a
S56D mutation in the CD site of wildtype parvalbumin, indicating that the mutation does not
significantly alter the secondary structure of the protein (Figure 4.16). For varying ratios of
terbium, the helical character increases for concentrations up to 5mM terbium under low and
high salt conditions. Thus, though terbium appears to increase the stability of ProCA-32, salt
plays little role in affecting the stabilization.
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Figure 4.16. Far UV spectra of 6 µM ProCA-32 in the presence varying protein to terbium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.5.4. ProCA-33
It has been well established that the alpha-helical fold of ProCA-33 is maintained with
introduction of an E60D mutation in the CD site of wildtype parvalbumin (Figure 4.17). In the
presence of increasing ratios of terbium in the absence of EGTA treatment at low and high salt
concentrations, the protein maintains its native α-helical character (Figure 4.17). For varying
ratios of terbium, the helical content increases for all ratios and concentrations under low salt
conditions. Only minor spectral changes are associated with high salt conditions indicating that
the presence of high salt helps to stabilize the secondary structure of the protein in the presence
of increasing concentrations of terbium.
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Figure 4.17. Far UV spectra of 6 µM ProCA-33 in the presence varying protein to terbium ratios.
(A) Low salt conditions. (B) High salt conditions. A buffer of 10mM Tris/HCl chelex pH 7.4
(100 mM NaCl) was used.
4.6. Summary of Metal-Dependent Secondary Structural Changes
It has been established that ProCA-30 maintains its native secondary structure following
bacterial overexpression and purification. This is also confirmed by published CD spectra of
ProCA-30 [39]. It was then investigated how the secondary structure of ProCA-31, ProCA-32,
and ProCA-33 changed under extremely high concentrations of varying metals (Figure 4.184.20).

.
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Figure 4.18. CD Spectrum of 6 µM ProCA-31 in the Presence of 5mM Metals. (A) In the
presence of 5mM EGTA. (B) No EGTA treatment.

Figure 4.19. CD Spectrum of 6 µM ProCA-32 in the Presence of 5mM Metals. (A) In the
presence of 5mM EGTA. (B) No EGTA treatment.
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Figure 4.20. CD Spectrum of 6 µM ProCA-33 in the Presence of 5mM Metals in the absence of
EGTA.
In the presence of 5mM EGTA and 5mM Tb3+ or Gd3+, the α-helical content of ProCA31 and ProCA-32 decreases in helicity and the spectrum shifts to a random coil (Figures 4.184.20). No protein precipitation was noted. There are a number of possible explanations for the
random coil formation noted for ProCA-31 and ProCA-32 the presence of 5mM gadolinium and
terbium The first may be due to nonspecific binding of metal ions to various sites on the protein,
disrupting the hydrogen bonds helping to maintain the protein’s native structure. The second
explanation may be due to pH effects induced as EGTA binds the metal ions (Table 4.1). For
every EGTA that binds a metal ion, four protons are released, decreasing the pH of the system.
Though the CD samples are immersed in a buffering system of 10mM Tris/HCl, the 10mM
concentration of Tris/HCl may not be sufficient to balance or maintain the pH environment of
the sample at pH 7.4. If the conformation of the protein changes from an alpha helix to a random
coil at 5mM concentration of these two metals in the absence of EGTA, one can safely assume
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that the induction of conformational change was due to nonspecific binding of the metal ion to
the protein instead of due to pH changes. This in fact proved to be the case.
At 5mM Mg2+, Ca2+, Tb3+, or Gd3+ in the absence of EGTA, the ProCA-31, ProCA-32,
and ProCA-33 maintain the native structure. The helical content of ProCA-31 appears to
decrease in the presence of calcium and increase in the presence of magnesium. Possible
explanations for these phenomena are not well understood. One would anticipate that the helicity
of ProCA-31 would increase in the presence of calcium since it has a much stronger binding
affinity to this particular metal than magnesium. The helical content of ProCA-33 appears to
increase in the presence of all tested metals at 5mM concentration and decrease in the presence
of EGTA. One can draw the presumption that the presence of the tested metals enhances the
structural stability of ProCA-33.
Table 4.1. pH Effects Observed Before and After the Addition of EGTA.

Mg2+
Ca2+
Tb3+
Gd3+

ProCA-30
ProCA-31
ProCA-32
ProCA-33
10mM 10mM 10mM 10mM 10mM 10mM 10mM 10mM
metal metal metal metal metal metal metal metal
and
and
and
and
5mM
5mM
5mM
5mM
EGTA
EGTA
EGTA
EGTA
7.51
6.77
7.50
6.80
7.49
6.86
7.46
6.85
7.36
4.53
7.39
4.39
7.41
4.42
7.42
4.42
2.23
2.29
2.33
2.27
6.49
6.65
6.60
6.63
6.70
2.32
6.54
2.30
6.78
2.35
6.73
2.35

In the presence of varying metal ratios in the absence of EGTA treatment at low and high
salt concentrations, the proteins maintain their native α-helical character. Pronounced spectral
differences are primarily seen between the low and high salt forms of the protein. Significant
structural changes were predominately noted at concentration of 1mM metal and higher. It’s
reasonable to assume that the background concentration or “contamination” of metals is likely
90

above 6µM. Therefore, although the buffer signals were subtracted from the metal-contrast agent
signals, the added magnesium, calcium, gadolinium, and terbium for 1:1 and 1:2 protein to metal
ratios may not be sufficient for displacing resting calcium or magnesium in the CD and EF
binding sites. Thus, only minor spectral changes were noted.
In summary, one can conclude that all members of Class ProCA-3 retained the native alphahelical fold. The introduction of mutations into the skeletal design of Class ProCA-3 did not
significantly alter the secondary structure of the protein and the presence of high salt did little to
destabilize the structure. Special attention should be paid for significant pH changes following
the addition of high concentration of metals in the presence of EDTA. Furthermore, the members
of this class exhibit strong secondary structure stability against high concentrations of Mg2+,
Ca2+, Tb3+, or Gd3+, allowing one to infer that an excellent scaffold structure chosen for contrast
agent design.
4.7. Determined Metal Binding Affinities of Class ProCA-3
For the purposes of presenting a more comprehensive study of the members of Class
ProCA-3 agents, the binding affinity of each agent, with the exception of ProCA-30, to calcium,
terbium, and gadolinium was determined by senior researcher David Xue. Using a competitive
metal titration aided by fluorescence spectroscopy, 20µM of protein in 100mM Tris/HCl 100mM
NaCl chelex pH 7.4 was initially saturated with terbium and the binding affinity (kD) of the
protein to terbium was calculated using the Hill equation. Then, terbium was competitively
competed out by increasing concentrations of either calcium or gadolinium. Using the equation
in Figure 4.21 below, the binding affinity of the protein to either calcium or gadolinium was
approximated. ProCA-32 was found to have the highest affinity for gadolinium compared to the
other members studied. The remaining kD values for each agent are listed in Figure 4.22.
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Figure 4.21. Class ProCA-3 metal binding ability.
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5. RELAXIVITY MEASURES
5.1. Introduction
As discussed in chapter 1 (section 1.1.2), relaxivity is a quantitative term used to reflect
the intrinsic contrast capability of a contrast agent per gadolinium ion. The measured relaxivity
is governed by the sample prep conditions and the relaxation properties of the agent discussed in
chapter 1. Thus, it is important to determine the conditions for sample preparation. This chapter
describes studies on the required sample volume, incubation time frame, and metal equilibration
for accurate in vitro relaxation time measurements. Additionally, two different protocols for
measuring relaxivity were implemented to determine how the relaxivity of the contrast agents
change when bound to one gadolinium versus two and to accurately determine the maximum
relaxivity and binding mode. The effect of salt on the measured relaxivity of the members of
Class ProCA-3 was also investigated
The conditions for measuring relaxivity as they relate to the effect of sample volumetric
changes, effect of sample incubation time, and extent of time required for metal equilibration
were first determined. To determine the effect an increase in volume has on the relaxation times,
the relaxation times of low concentrations of free gadolinium at 200µL and 400µL volumes were
measured. Figure 5.1A illustrates that the differences in T1 relaxation times are within the range
of fitting error (with the exception of 10µM gadolinium) while more notable differences were
observed in T2 relaxation times. However, these results are not reliable, as they are within the
range of residual background metal concentrations as later explained in the details outlining
optimization of the fixed gadolinium protocol. Because less pronounced changes were noted in
T1, it was decided to continue using 200µL volumes for relaxivity measurements.
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To determine the effects of different incubation times at 37˚C on relaxation times, a
sample of 50µM ProCA-32 and 100µM Gd3+ was arbitrarily chosen to note changes for 5
minutes, 4 hours, and overnight incubation. Figure 5.1B yields that there are only minor
variances in the relaxation times as a function of incubation time. SDS-PAGE analysis indicates
that the protein is stable over the measured incubation times. However, it is important to note the
inconsistency in the density of the bands for lanes 1 and 2 of the gel in Figure 5.1C. This was
likely due to a sample loading human error. Nevertheless, it appears that the length of incubation
up to overnight conditions at 37˚C has no significant effect on the relaxation times.
To determine the extent of metal equilibration time necessary to measure accurate
relaxation times, a ProCA-31 relaxivity sample, pseudo-form of ProCA-30, was chosen under
the presumption that the contrast agent bearing the weakest binding affinity to gadolinium
(found by Senior PhD researcher David Xue) would require the longest amount of time to bind
the metal compared to ProCA-32 and ProCA-33. Therefore, ProCA-31 was prepared in a 1 to 2
ratio (50µM ProCA-31 and 100µM gadolinium) and the concentration of free metal following 30
minutes, 3 hours, and overnight equilibration was measured using a weak calcium-binding dye
Rhodamine-5N (Figure 5.1C). Theoretically, the optimal equilibration time will have the lowest
concentration of free metal. Of the observed time points, it was found that overnight
equilibration yielded the lowest concentration of free metals. Therefore, it was determined that
the relaxivity samples for future measure (fixed gadolinium experiments) would be equilibrated
overnight.
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5.1. Optimizing Relaxivity Sample Prep Conditions. (A) Volumetric observations. (B)
Incubation time assay. (C) Metal equilibration schemes.
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5.2. Determining Relaxivity Using Two Different Protocols
The parameter relaxivity is directly proportion to the amount of signal intensity visualized in
an MR image. Therefore, the higher the relaxivity, the greater the signal intensity and thus a
more improved differentiated image of normal versus diseased tissues. Here, we use two
different methods to determine an accurate relaxivity value. The traditional method for
measuring relaxivity is well established. It is commonly implemented to measure the relaxivity
of commercially available contrast agents. Using this method, the relaxation times of different
protein-gadolinium samples prepared at a fixed ratio were measured. The slope of the linear
plots represents the relaxivity of the sample at the fixed ratio. The second method used involves
fixing the gadolinium concentration and increasing the protein concentration. It was originally
developed to design a novel way of using a relaxometer to measure the binding affinity of a
protein to gadolinium. Details into extrapolating the dissociation constant from the relaxivity
data are not discussed here. This newly developed method also allows one to eliminate effects on
relaxivity associated with the interference of non-specific binding of gadolinium with the
contrast agents at significantly high concentrations of gadolinium. Using this method, one can
obtain the maximum relaxivity of the protein-gadolinium complex by averaging the relaxivity of
ratios occurring in the plateau portion of the curve formed during the experiment. Furthermore,
this method allows one to gain insight into the binding stoichiometry of developed contrast
agents. The latter two uses for the newly developed protocol are discussed in this thesis.
5.3. Traditional Methods for Measurement
Class ProCA-3 Agents are multi-binding site contrast agents that can selectively bind a
maximum of two metal ions, one in their CD and EF sites respectively. We assume that there is
little to no nonspecific binding of gadolinium at the experimental concentrations used, as we do
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not exceed a 1:2 protein to gadolinium ratio in our sample preparative methods. However, this
must be further investigated. Though secondary structural analysis was performed, it is unclear
at this time how increasing concentrations of metal affect the tertiary structure of the agents.
Also, it has not been determined whether decreasing the ratio of protein to gadolinium in
solution will lead to significant global structural changes. This also must be further investigated.
Nevertheless, it has been proposed that increasing the number of gadolinium binding sites
shortens the longitudinal and transverse relaxation times, thus increasing the relaxivity. For this
reason, the relaxivity for the 1:2 ratio is expected to be higher than that of the 1:1 ratio.
However, this phenomenon is not observed under low or high salt conditions (see section 2.6 for
experimental details).
Using the traditional protocol mentioned in chapter 2 (section 2.6), the relaxation times T1
and T2 were measured at fixed protein to gadolinium ratios of 1:1 and 1:2 under low and high
salt conditions. The concentration (µM) ratios of protein to gadolinium for the 1:1 experiment
were as follows: 10:10, 20:20, 30:30, 40:40, and 50:50. The concentration (µM) ratios of protein
to gadolinium for the 1:2 experiment were as follows: 10:20, 20:40, 30:60, 40:80, and 50:100.
This concentration dependence assay allows for one to calculate the in vitro relaxivity as a
function of protein concentration (or of gadolinium concentration for 1:1) by taking the slope of
the line formed by the series of fixed protein to gadolinium ratios. To calculate the relaxivity of
the 1:2 experiment as a function of gadolinium concentration, the slope of the line must be
halved. Otherwise, the relaxivity as a function of the protein concentration for the 1:2
experiments can be taken from the slope of the line. Tables 5.1 and 5.2 reveal the calculated
relaxivity values per gadolinium ion for the developed contrast agents discussed in this thesis.
Table 5.1. In vitro relaxivity of designed contrast agents under low salt conditions.
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1:1

1:2

R1 (mM-1 s-1)
R2 (mM-1 s-1)
R1 (mM-1 s-1)
Developed
Contrast Agent
3.8
4.5
3.8
Gd DTPA
28.13 ± 1
36.75 ± 1
27.20 ± 1
ProCA-30
28.10 ± 3
36.25 ± 4
31.87 ± 4
ProCA-31
7.64
±
0.2
10.04
±
1
20.40
±6
ProCA-32
5.07 ± 0.1
5.49 ± 1
8.08 ± 1
ProCA-33
The samples were prepared in 10mM Tris/HCl chelex pH 7.44.

R2 (mM-1 s-1)
4.5
35.42 ± 2
41.60 ± 4
26.64 ± 7
10.43 ± 1

Table 5.2. In vitro relaxivity of designed contrast agents under high salt conditions.
1:1

1:2

R1 (mM-1 s-1)
R2 (mM-1 s-1)
R1 (mM-1 s-1)
Developed
Contrast Agent
3.8
4.5
3.8
Gd DTPA
27.33 ± 2
36.11 ± 2
28.32 ± 1
ProCA-30
31.38 ± 0.3
40.86 ± 1
28.32 ± 2
ProCA-31
9.46 ± 0.3
12.17 ± 0.3
21.07 ± 1
ProCA-32
5.05 ± 0.2
5.55 ± 1
7.82 ± 1
ProCA-33
The samples were prepared in 10mM Tris/HCl chelex 100mM NaCl pH 7.44.

R2 (mM-1 s-1)
4.5
33.36 ± 6
36.52 ± 7
27.52 ± 1
8.62 ± 2

As one can observe, the T1 and T2 times for ProCA-30 shorten as the protein to metal ratio
increases for both low and high salt conditions (Figure 5.2).
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Figure 5.2. ProCA-30 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology.
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions.
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The average R1 and R2 values for ProCA-30 under low salt conditions for a 1:1 binding ratio
are 28.13 ± 1 mM-1 s-1 and 36.75 ± 1 mM-1s-1, respectively while for a 1:2 binding ratio, the
values are 27.20 ± 1 mM-1 s-1 and 35.42 ± 2 mM-1 s-1, respectively. Similarly, the average R1 and
R2 values or ProCA-30 under high salt conditions for a 1:1 binding ratio are 27.33 ± 2 mM-1 s-1
and 36.11 ± 2 mM-1 s-1, respectively while for a 1:2 binding ratio, the average relaxivities are
28.32 mM-1 s-1 ± 1 and 33.36 ± 6 mM-1 s-1, R1 and R2 respectively (Figure 5.3).
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Figure 5.3. ProCA-30 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear plots
under low salt conditions. (B) Linear plots under high salt conditions.
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There were little differences between the 1:1 and 1:2 ratios under both low and high salt
conditions, indicating that the presence of high salt does little to significantly alter the relaxivity
values. Furthermore, the saturation of both binding sites in ProCA-30 does not significantly
enhance the relaxivity. Correlating this with the CD data in chapter 4 (section 4.4.1), although
increasing concentrations of gadolinium appears to destabilize the secondary structure under
both low and high salt conditions, the presence of high salt does little to disturb metal-dependent
structural changes (Figure 4.10). Additionally, the nominal CD spectral differences associated
with a 1 to 1 and 1 to 2 binding ratio are consistent with the little variance in relaxivity values for
these ratios under both salt conditions. Moreover, these values yield exciting results, showing
that the relaxivity 1 and 2 values of ProCA-30 are significantly higher than those of commercial
Gd-DTPA of 3.8 mM-1 s-1 and 4.5 mM-1 s-1, respectively.
Like that of ProCA-30, the T1 and T2 times of ProCA-31 shorten as the protein to metal ratio
increases for both low and high salt conditions (Figure 5.4).
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Figure 5.4. ProCA-31 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology.
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions.
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The average R1 and R2 values of ProCA-31 under low salt conditions for a 1:1 binding ratio
are 28.10 ± 3 mM-1 s-1 and 36.32 ± 4 mM-1s-1, respectively while for a 1:2 binding ratio, the
values are 31.87 ± 4 mM-1 s-1 and 41.60 ± 4 mM-1 s-1, respectively. Under high salt conditions
for a 1:1 binding ratio, the average R1 and R2 values are 31.38 ± 0.3 mM-1 s-1 and 40.86 ± 1 mM1 1

s , respectively while for a 1:2 binding ratio under high salt conditions, the averaged R1 and R2

values are 28.32 ± 2 mM-1 s-1 and 36.52 ± 7 mM-1 s-1, respectively (Figure 5.5). Like ProCA-30,
the presence of high salt does not significantly alter the relaxation times. Correlating this with
the CD data in chapter 4 (section 4.4.2), although increasing concentrations of gadolinium
appears to destabilize ProCA-31 secondary structure under low salt conditions, the presence of
high salt helps stabilize the metal-dependent structural changes (Figure 4.11). Additionally, the
CD spectral differences associated with a 1 to 1 and 1 to 2 binding ratio are inconsistent with the
relaxivity values under low salt conditions and consistent with the little variance in relaxivity
values for these ratios under high salt conditions. It is apparent that the structural destabilization
under low salt conditions is not significant enough to alter the relaxivity values.
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Figure 5.5. ProCA-31 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear
plots under low salt conditions. (B) Linear plots under high salt conditions.
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It appears that ProCA-30 and ProCA-31 have nearly identical relaxivity values. If one
recalls, these two agents represent the control and pseudo-control agents for Class ProCA-3. It is
apparent that the F103W mutation made just outside of the EF loop (ProCA-31) of the skeletal
structure of the protein does little to perturb its intrinsic relaxation times. These results are
exciting, as they not only reveal relaxivity 1 and 2 values significantly higher than those of
commercial Gd-DTPA of 3.8 mM-1 s-1 and 4.5 mM-1 s-1, respectively, but also allow one to
conclude that the introduction of a tryptophan residue at position 103 proves as an effective tool
to potentially monitor the intrinsic fluorescence of Class ProCA-3 agents for future structural
and metal-binding studies. A high salt environment only slightly lowers the relaxivity values for
ProCA-31 as compared to low salt conditions.
The relaxivity of ProCA-32 yields interesting results. As one can observe, the T1 and T2
values shorten as the protein to metal ratio increases for both low and high salt conditions
(Figure 5.6).
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Figure 5.6. ProCA-32 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology.
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions.
107

The average R1 and R2 values for ProCA-32 under low salt conditions for a 1:1 binding ratio
are 7.64 ± 0.2 mM-1 s-1 and 10.04 ± 1 mM-1s-1, respectively while for a 1:2 binding ratio, the
values are 20.40 ± 6 mM-1 s-1 and 26.64 ± 7 mM-1 s-1, respectively. The average R1 and R2
values under high salt conditions for a 1:1 binding ratio are 9.46 ± 0.3 mM-1 s-1 and 12.17 ± 0.3
mM-1 s-1, respectively while for a 1:2 binding ratio, the values are 21.07 ± 1 mM-1 s-1 and 27.52 ±
1 mM-1 s-1, respectively (Figure 5.7).
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Figure 5.7. ProCA-32 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear plots
under low salt conditions. (B) Linear plots under high salt conditions.
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The 1 to 1 relaxivity values under low salt conditions are slightly lower than those under
high salt conditions. However, the 1 to 2 binding ratios under both salt conditions are within the
range of error. This indicates that high salt has a more positive effect on increasing the relaxivity
at the 1 to 1 ratio versus the 1 to 2 ratio. As one can infer, the 1:2 ratios are nearly 2.5 times
higher that of the 1:1 under both low and high salt conditions. Correlating this with the CD data
in chapter 4 (section 4.4.3), increasing concentrations of gadolinium appears to stabilize ProCA32 secondary structure under both salt conditions. However, as with the 1 to 1 relaxivity
samples, the presence of high salt helps better stabilize the metal-dependent structural changes
(Figure 4.12). The lack of CD spectral differences associated with a 1 to 1 and 1 to 2 binding
ratio under both salt conditions is inconsistent with the increase in relaxivity values for these
ratios. It appears that the measured relaxation times of ProCA-31 are independent of metalinduced changes in secondary structure.
Previous binding studies of this class of agents have shown that ProCA-32 bears the highest
binding affinity to gadolinium. Here, it appears that the introduction of an additional charged
residue into the CD site of the contrast agent significantly improves the relaxivity of the contrast
agent at a 1:2 ratio versus a 1:1 ratio. These results are exciting, revealing relaxivity 1 and 2
values significantly higher than those of commercial Gd-DTPA of 3.8 mM-1 s-1 and 4.5 mM-1 s-1,
respectively. The presence of high salt does little to significantly alter the relaxivity values. By
design, the site-directed mutagenesis approach has improved the relaxivity of the agent
following metal saturation. However, it’s important to note here that the relaxivity of ProCA-30
and ProCA-31, void of CD or EF site mutations, maintain higher relaxivity values than that of
ProCA-32. These results are not well understood. It’s possible that the introduction of an
additional charged residue enhances dimerization of the agent in solution, hampering the
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relaxivity or rather increasing the relaxation times measured. This negative effect could possibly
be related to significantly slowing the rotational correlation time.
Like ProCA-32, the relaxivity results for ProCA-33 yield unexpected values. Like the
previously mentioned members of Class ProCA-3 agents, the T1 and T2 intensity values for
ProCA-33 decrease as the protein to metal ratio decreases for both low and high salt conditions
(Figure 5.8).
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Figure 5.8. ProCA-33 T1 and T2 Signal Intensity Plots per traditional relaxivity methodology.
(A) Signal intensity under low salt conditions. (B) Signal intensity under high salt conditions.
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The average R1 and R2 values under low salt conditions for a 1:1 binding ratio are 5.065 ±
0.1 mM-1 s-1 and 5.49 ± 1 mM-1 s-1, respectively while that for a 1:2 binding ratio are 8.08 ± 1
mM-1 s-1 and 10.43 ± 1 mM-1 s-1, respectively. The average R1 and R2 values under high salt
conditions for a 1:1 binding ratio are 5.05 ± 0.2 mM-1 s-1 and 5.55 ± 0.3 mM-1 s-1, respectively
while that for a 1:2 binding ratio are 7.82 ± 1 mM-1 s-1 and 8.62 ± 1 mM-1 s-1, respectively
(Figure 5.9).
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Figure 5.9. ProCA-33 R1 and R2 linear plots of 1/T1,2 vs. protein concentration. (A) Linear plots
under low salt conditions. (B) Linear plots under high salt conditions.
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The presence of high salt does little to significantly alter the relaxivity values. Furthermore,
the 1:2 ratios are only slightly higher than that of the 1:1 under both low and high salt conditions.
Correlating this with the CD data in chapter 4 (section 4.4.4), increasing concentrations of
gadolinium appears to stabilize ProCA-32 secondary structure under low salt conditions (Figure
4.12). The presence of high salt appears to stabilize the metal-dependent structural changes
(Figure 4.12). The lack of CD spectral differences associated with a 1 to 1 and 1 to 2 binding
ratio under both salt conditions is consistent with the measured relaxivity values for these ratios.
The ProCA-33 results do not reveal relaxivity 1 and 2 values significantly higher than those
of commercial Gd-DTPA of 3.8 mM-1 s-1and 4.5 mM-1 s-1, respectively. It seems the introduction
of a slightly shorter residue in the CD site of the skeletal design of the agent (E60D) may perturb
the intrinsic properties of the CD gadolinium binding site and hamper the optimal effects
associated with the rate of water exchange in the metal binding site. Hence, there are minimal
changes in relaxivity associated with the saturation of the protein agent with two gadolinium ions
versus one metal ion. Additionally, the low relaxivity values may also be due to the same
dimerization phenomenon given as an explanation for ProCA-32’s lower relaxivity. The notably
low relaxivity values for ProCA-33 compared to those of previously discussed members of Class
ProCA-3 requires further investigation.
In summary, it appears that the measured relaxivity values are not necessarily affected by
metal-induced structural changes. ProCA-32 is the only member of Class ProCA-3 whose
increase in relaxivity from the 1 to 1 to the 1 to 2 ratio under both salt conditions doesn’t
correlate significant changes in the protein’s secondary structure. The remaining members yield
positive correlations with the CD data between their consistent relaxivity values under both salt
conditions at 1 to 1 and 1 to 2 ratios.
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5.4. Measuring Relaxivity by Fixing [Gd3+] and Increasing Protein Concentration
The primary goal of this experiment is multifaceted. Using different fixed concentrations
of gadolinium (10, 50, or 100 µM) with increasing protein concentration, we are able to
determine the optimal range for approximating the binding affinity of gadolinium to the protein
used, the binding stoichiometry (that is whether the protein binds one, two, etc gadolinium ions),
and the average relaxivity. It’s important to note here that for proteins with multiple binding
sites, an assumption has been made that all the binding sites have equal binding affinities (based
on published results of parvalbumin for example) and the data can thus be fit by a 1 to 1
equation. This method is still in further development and therefore not mentioned in this
protocol. Still, using the optimal fixed concentration of gadolinium and increasing the protein
concentration, we can effectively determine the binding mode of the protein and approximate the
maximum relaxivity 1 and 2 (R1 and R2) of the contrast agent used.
5.4.1. Protocol Optimization Using ProCA-30
To determine whether the protein to metal binding is truly at a 1:2 ratio, GdCl3 was fixed
at varying concentrations and the concentration of protein was steadily increased. Figure 5.10
depicts the change in relaxation times of ProCA-30 as the ratio of protein to gadolinium
increases for fixed 10µM, 50µM, and 100µM gadolinium.
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Figure 5.10. ProCA-30 T1 and T2 Signal Intensity Plots per fixed 10, 50, and 100µM Gd3+
concentration.
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The protein concentration was then plotted as a function of the reciprocal T values to
yield a hyperbolic curve. If the binding is 1:1, the curve will reach saturation at a protein
concentration equal to that of the fixed Gd3+ concentration. If the binding is 1:2, the curve will
reach saturation at a protein concentration equal to one-half of the fixed Gd3+ concentration
(Figure 5.11).
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Figure 5.11. Relaxivity curves of ProCA-33 at different fixed concentrations of Gd3+. (A)
ProCA-30 at fixed 10µM [Gd3+]. (B) ProCA-30 at fixed 50µM [Gd3+]. (C) ProCA-30 at fixed
100µM [Gd3+].
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At a fixed 10µM concentration of Gd3+, the curve reaches saturation at 10µM of protein
concentration. It appears that the binding is 1:1 at this concentration. However, there are minimal
changes in the relaxation times as the ratio of protein to gadolinium increases, indicating that the
measured values have a fairly large range of error. Furthermore, it’s likely that this low fixed
concentration of gadolinium is not ideal for determining the binding mode or relaxivity, as
background metal contamination due to calcium or magnesium may significantly interfere with
gadolinium binding to the designed metal binding site in the contrast agent. For example, if
calcium background “contamination” is equal to or higher than that of fixed 10µM gadolinium,
then at a 1:1 protein to gadolinium concentration ratio, the ratio of protein to gadolinium may be
equal to that of protein to calcium. This implies that the binding sites of the contrast agent may
be saturated with calcium and gadolinium and thus gadolinium cannot completely displace
calcium from the binding site at such a low fixed concentration. Thus, the relaxivity of the
contrast agent cannot be accurately measured. At fixed 50 and 100µM concentrations of Gd3+,
the curves reach saturation at one-half of their respective fixed Gd3+ concentrations (Figure 5.11
B-C). The change in relaxation times are much more pronounced as the ratio of protein to
gadolinium increases when compared to that of a fixed 10µM concentration of Gd3+. From our
experiments thus far, we have found that a fixed concentration of 100 µM gadolinium (and to a
slightly lesser degree 50 µM) yields the most accurate range for measuring changes in relaxation
times with increasing protein concentration at a fixed gadolinium value. Thus, this concentration
range is optimal for determining the binding mode and average relaxivity of a contrast agent.
Both the fixed 50µM and 100µM concentrations of Gd3+ indicate that ProCA-30 binds
Gd3+ in a 1:2 protein to gadolinium ratio and the possibility of nonspecific binding can be
excluded from the potential alternative binding modes of the protein (Figure 5.11 B-C). The
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average R1 and R2 for ProCA-30 were calculated to be 31 ± 2 mM-1 s-1 and 42 ± 2 mM-1 s-1,
respectively. These values are nearly identical to those calculated from the traditional method
(Table 5.2).
5.4.2. ProCA-31
Using a fixed concentration of 100µM Gd3+, the signal intensity trends of relaxation time
follow a similar pattern to that of ProCA-30 (Figure 5.12). The relaxation times shorten as the
ratio of protein to gadolinium increases until the protein becomes fully saturated with
gadolinium.

Figure 5.12. ProCA-31 T1 and T2 signal intensity plots at a fixed [Gd3+] of 100µM.
The change in relaxation times reaches saturation at 50µM ProCA-31, indicating that the
binding is 1:2. The average R1 and R2 values calculated from the saturated portion of the curve
in are 42.87 ± 1 mM-1 s-1 and 55.75 ± 1 mM-1 s-1, respectively (Figure 5.13). Comparing these
values to that of the 1:2 relaxivity values approximated by the traditional method, ProCA-31 has
a higher relaxivity (Table 5.2). Furthermore, it maintains relaxivity values nearly ten times that
of ProCA-30. The reasons behind this significant difference in R1 and R2 values are not well
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understood. One could postulate that the addition of a tryptophan residue just outside of the EF
gadolinium binding site changes the inner sphere water coordination, slowing the rate of water
molecule exchange with the bulk solvent. As a result, the relaxation time is shortened and the
relaxivity increases. Still, this must be further investigated.

Figure 5.13. Relaxivity curves of ProCA-31 at a fixed 100µM concentration of Gd3+.
5.4.3. ProCA-32
Like ProCA-30 and ProCA-31, the relaxation times shorten as the ratio of protein to
gadolinium increases until the protein reaches a 1:2 concentration ratio with gadolinium.
However, as the ratio of protein to gadolinium begins to increase above this ratio, the relaxation
times begin to steadily lengthen (Figure 5.14, Figure 5.15). Thus, the overall relaxivity
calculated from the slope of the ratios above 1:2 yield a relaxivity value significantly lower than
anticipated. Using a fixed concentration of 100µM Gd3+, the change in decreasing relaxation
times peaks at 50µM ProCA-32, indicating that the binding is 1:2. The average R1 and R2 values
calculated from the saturated portion of the curve in Figure 5.15 are 15.39 ± 0.4 mM-1 s-1 and
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19.95 ± 1 mM-1 s-1, respectively. Comparing these values to that of the 1:2 relaxivity values
approximated by the traditional methods, ProCA-32 has a lower relaxivity (Table 5.2).
It is unclear why the curve rapidly drops at ratios higher than 1:2 (Figure 5.15). The
reasons behind this observed phenomenon are not well understood. One possible explanation
could be due to the heterogeneous nature of ProCA-32 gadolinium binding sites. The serine to
aspartic acid mutation made at position 56 is identical to the serine to aspartic acid mutation
made at position 55 of Michael Henzl’s studies of rat α- and β-parvalbumins neglecting our
phenylalanine to tryptophan mutation added at position 103 outside of the EF loop (Henzl’s
numbering of parvalbumin residues counts the first methionine cleaved as residue number one
whereas our studies do not) [34]. Henzl’s studies report macroscopic stepwise calcium binding
constants for the S55D mutation in buffer 0.025M Hepes 0.15M NaCl pH 7.4 at 25˚C, where K1
(M-1) is 2.1 (0.2) x 108 and K2 (M-1) is 5.0 (0.2) x 107 [34]. Assuming that the properties of
gadolinium binding are comparable to that of calcium binding due to their positive charge and
comparable ionic radii, one can assume that this mutation maintains ten-fold differentiated metal
binding sites. We assume here that the CD loop is the higher affinity metal binding site while the
EF loop is the weaker metal binding site, as the ProCA-32 mutation yields a higher overall
dissociation constants compared to the pseudo wildtype ProCA-31 (Figure 4.21) [34]. This
provides an explanation for the attenuated increase in relaxation times above 50µM ProCA-32.
At concentrations of 50µM and below, the relaxivity signal is predominantly due to saturation of
both the weak (lower affinity EF site) and strong (higher affinity CD site) metal binding sites, as
the protein concentration is significantly lower than that of the fixed gadolinium concentration of
100. The slope of this portion of the curve yields the average relaxivity of ProCA-32 and excess
free gadolinium. Above 50µM protein, the introduction of excess protein or unoccupied metal
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binding sites “recruits” gadolinium ions to the stronger metal binding site, leaving the weaker
metal binding sites unoccupied. Therefore, the increasing concentration of protein reduces the
concentration of total saturated metal binding sites and relaxivity decreases. The slope of the
curve above 50µM ProCA-32 corresponds to the relaxivity of the strong metal binding sites.

Figure 5.14. ProCA-32 T1 and T2 signal intensity plots at a fixed [Gd3+] of 100µM.

Figure 5.15. Relaxivity curves of ProCA-32 at a fixed 100µM concentration of Gd3+.
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5.4.4. ProCA-33
The relaxation times of ProCA-33 shorten as the ratio of protein to gadolinium increases
until the protein reaches a 1:3 concentration ratio with gadolinium (Figure 5.16, Figure 5.17).
The relaxation times rapidly drop at the 1:2 ratio. Above the 1:2 ratio, the relaxation times begin
to plateau. Because of this unexpected lengthening of relaxation times, the overall relaxivity
calculated from the slope of the ratios above 1:2 yield a relaxivity value significantly lower than
anticipated. Furthermore, using a fixed concentration of 100µM Gd3+, the change in decreasing
relaxation times peaks at 38µM ProCA-33 indicating that the binding is 1:3. However, this
phenomenon is not well understood. It’s possible that at this concentration ratio, the dimerization
of the protein begins to occur. To further address the binding mode of ProCA-33, a reverse
titration of the fixed gadolinium experiment was performed. ProCA-33 concentration was fixed
at 50µM and increasing amounts of gadolinium was titrated into the system up to a 1 to 4
ProCA-33: Gd3+ ratio (Figure 5.18). The sharp increase noted at the 100µM gadolinium indicates
that the binding is 1:2. Thus, devoid potential dimerization effects, ProCA-33 binds two
gadolinium ions. While the reverse titration method can provide more detailed information
concerning the binding mode, it cannot accurately represent the average relaxivity of a contrast
agent due to the variances in gadolinium concentration. Thus, the average R1 and R2 values
calculated from the saturated portion of the curve in Figure 5.17 are 7.16 ± 0.7 mM-1 s-1 and 8.34
± 1 mM-1 s-1, respectively. Comparing these values to that of the 1:2 relaxivity values
approximated by the traditional methods, the values for ProCA-33 are nearly identical (Table
5.2).
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Figure 5.16. ProCA-33 T1 and T2 signal intensity plots at a fixed [Gd3+] of 100µM.

Figure 5.17. Relaxivity curves of ProCA-33 at a fixed 100µM concentration of Gd3+.
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Figure 5.18. ProCA-33 reverse titration for binding mode determination.

It was suggested that the sudden increase in relaxation times noted for ProCA-32 and
ProCA-33 (Figures 5.15 and 5.17) was due to the presence of excess EDTA introduced into the
system during the FPLC separation purification process. Theoretically, excess EDTA at
comparable concentrations of contrast agent would competitively compete with the protein for
gadolinium. The reduced availability of free gadolinium would result in an increased
concentration of free protein in the measured sample and thus a longer relaxation time (lower
relaxivity). Because the significant change in relaxation times was not noted for high
concentrations of ProCA-30 and ProCA-31, for this argument to be valid, the process for
reducing the concentration of EDTA via dialysis prior to relaxivity experiments may not have
been as efficient for ProCA-32 and ProCA-33. This is highly unlikely since identical expression
and purification procedures were implemented for isolation of all members of Class ProCA-3
agents. Still, to investigate whether ProCA-32 and ProCA-33 had significant amounts of excess
chelator present in their stock samples relative to ProCA-31, a fluorescence titration with
rhodamine-5N was completed by senior research David Xue. The instrumental conditions for
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this experiment were identical to those listed in chapter 2 (section 2.5). Concentrations of 50µM
ProCA-31 (control), ProCA-32, and ProCA-33 were each combined with 1µM of dye in 10mM
Tris/HCl 100mM NaCl chelex pH 7.44. Increasing concentrations of gadolinium were titrated
into the system (Figure 5.19).

Figure 5.19. Determination of excess EDTA in contrast agent samples. (A) Fluorescence
intensity spectrum of ProCA-31. (B) Fluorescence intensity spectrum of ProCA-32. (C)
Fluorescence intensity spectrum of ProCA-33. Sample conditions: 1µM rhodamine-5N, 50µM
protein in 10mM Tris 100mM NaCl chelex pH 7.44.
Assuming that the binding of the tested agents to gadolinium is 1 to 2, the fluorescence
intensity above 100µM added gadolinium (1 to 2 ratio) should not increase if excess EDTA is
present. Here, EDTA would compete with rhodamine-5N for binding gadolinium. However, this
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effect is not observed. Above 50µM of added gadolinium, the fluorescence intensity sharply
increases for all tested contrast agents, allowing excess free gadolinium to bind to rhodamine-5N
(Figure 5.20). Due to the lack of points collected between 50µM and 100µM added gadolinium,
one cannot determine the whether the sharp increase exclusively occurs above 50µM added
gadolinium. This would provide further insight into the binding mode of the tested agents.
Nevertheless, this data indicates that not only is there very little free EDTA present in the protein
stock samples, but the concentration of this chelator does not vary from protein to protein.
Therefore, this phenomenon cannot be used to explain the lowered relaxivity. Additionally,
while this fluorescence titration method has the potential to offer insight into the lowered
relaxivity of ProCA-32 and ProCA-33, it does not effectively address the significant increase in
relaxation times at higher concentrations of protein. Thus, it is more likely that the effect seen for
ProCA-32 and ProCA-33 lowered relaxivities is due to dimerization or the heterogeneous nature
of the gadolinium metal binding sites for the reasons previously outlined in this chapter.

Figure 5.20. Effects of increasing concentrations of gadolinium on fluorescence intensity.
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While dimerization effects may present a possible explanation for the significant increase
in relaxation times for ProCA-33 in Figure 5.17, it is important to note the sharp increase in
relaxation times above 38µM protein compared to the attenuated increase in that of ProCA-32 in
Figure 5.15. If the effects seen were due to dimerization effects, the slope of increasing
relaxation times for both ProCA-32 and ProCA-33 should be nearly identical. Though each
variant maintains an aspartate mutation at different positions within the CD site, one would not
expect that this positioning would significantly affect the relative dimerization potential of each
agent. Thus, the heterogeneity of the metal binding sites presents a more plausible explanation
for this phenomena observed in both ProCA-32 and ProCA-33. The glutamate to aspartic acid
mutation made at position 60 is identical to the glutamate to aspartic acid mutation made at
position 59 of Michael Henzl’s studies of rat α- and β-parvalbumins (Henzl’s numbering of
parvalbumin residues counts the first methionine cleaved as residue number one whereas our
studies do not) [34]. These studies report that the macroscopic association constants for calcium
binding of the ProCA-33 mutation are as follows: K1 (M-1) is 1.2 (0.1) x 108 and K2 (M-1) is 7.8
(0.3) x 106 [34]. Here, we assume that the CD site is the weaker gadolinium affinity site
compared to that of the EF site in the E60D mutant (ProCA-33) compared to the wildtype
association constants of α-parvalbumin (ProCA-30) in Henzl’s paper [34]. Assuming that the
nature of calcium and gadolinium binding are similar for the reasons previously stated, it appears
that ProCA-33 has a lower overall metal binding affinity (Figure 4.21). Still, the increased
binding affinity differentiation between the CD and EF sites is enhanced in ProCA-33 compared
to ProCA-32, as there is nearly a 100-fold differentiation between the association constants of
ProCA-33 compared to the 10-fold difference in the ProCA-32 constants [34]. Therefore, a more
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drastic increase in relaxation times is noted above 38µM protein (Figure 5.17). Theoretically,
this increase should occur above 50µM protein. However, it’s possible that there is an error in
estimation of the protein concentration due to the inconsistencies in the reported molar extinction
coefficient for this variant. At concentrations of approximately 38-50µM and below, the
relaxivity signal is predominantly due to saturation of both the weak (lower affinity CD site) and
strong (higher affinity EF site) metal binding sites, as the protein concentration is significantly
lower than that of the fixed gadolinium concentration of 100. The slope of this portion of the
curve yields the average relaxivity of ProCA-33 and excess free gadolinium. Above 38-50µM
protein, the introduction of excess protein or unoccupied metal binding sites “recruits”
gadolinium ions to the stronger metal binding site, leaving the weaker metal binding sites
unoccupied. Therefore, the increasing concentration of protein reduces the concentration of total
saturated metal binding sites and relaxivity decreases. The slope of the curve above 38-50µM
ProCA-33 corresponds to the relaxivity of the strong metal binding sites.
5.5. Summary
Overall, both the traditional method of measurement and the fixed gadolinium
experiments yield comparable relaxivity values, with the exception of ProCA-32. ProCA-32 and
ProCA-33 maintain notably lower relaxivities compared to ProCA-30 and ProCA-31 members
which do not bear a CD site mutation. This is primarily due to the significant increase in
relaxation times following the 1:2 ratio for ProCA-32 and the 1:3 ratio for ProCA-33. As
previously explained, this is likely due to the heterogeneous nature of the metal-binding sites.
It appears that all members of Class ProCA-3 bind gadolinium in a 1:2 ratio. ProCA-33
appears to bind gadolinium in a 1:3 ratio by the fixed gadolinium method. However, a reverse
titration of the fixed gadolinium method allows one to conclude that the binding is 1:2. There are
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a number of plausible explanations provided as an explanation for the lowered relaxivities of
ProCA-32 and ProCA-33 compared to that of ProCA-30 and ProCA-31. Initially, dimerization
effects were assumed to be the cause for the drastic increase in relaxation times above the 1 to 2
ratio in ProCA-32 (Figure 5.15) and 1 to 3 ratio in ProCA-33 (Figure 5.17) due to the
introduction of additional charged residues in the CD site compared to that of ProCA-30 and
ProCA-31. However, this assumption does not address the gradual increase in relaxation times
for ProCA-32 versus the sharp increase for ProCA-33. A more plausible explanation for the
sharp increase in relaxation times is due to the heterogeneous nature of the metal binding sites
within class ProCA-3 agents. As noted by the fixed gadolinium curves in Figures 5.15 and 5.17,
initially, gadolinium occupies the strong affinity site (low relaxivity) site and then occupies the
weak affinity site (higher relaxivity). The 100-fold differentiation noted in ProCA-33 compared
to the 10-fold differentiation in ProCA-32 explains why a more pronounced increase in
relaxation times was noted for ProCA-33. At higher concentrations of protein, the fixed
concentration of gadolinium preferentially binds the strong metal binding affinity sites, reducing
the concentration of protein saturated and lowering the overall relaxivity measured. Thus, lower
relaxivities using the fixed gadolinium-increasing protein concentration method are noted for
ProCA-32 and ProCA-33. Our secondary structure results from circular dichroism in chapter 4
do not reveal any significant structural changes in the native structure of this class of contrast
agents due to the CD site mutations made in ProCA-32 and ProCA-33. To provide a more
concrete explanation to explain lower than expected relaxivity phenomenon noted by traditional
method calculations, further investigation is required.
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6. FINAL CONCLUSIONS AND FUTURE WORK
In summary, the current expression protocol used yields a high quantity of overexpressed
parvalbumin and its variants according to SDS Page gel analysis. However, this conclusion is
based on evidence of consistency in loading samples onto the gel and on the contingency that the
dense band observed at 12 kDa is primarily due to the presence of the desired protein. Minor
modifications can be made to the procedure by eliminating overnight growth for expression.
Though differences in optical density indicate enhanced cellular growth, overnight incubation
does not yield a significant difference in the amount of protein expressed compared to three to
four hours after induction.
Through the development of optimal streptomycin sulfate precipitation conditions and salt
gradient modification of the program used for FPLC Q-column separation, significant
improvements were made (from 31.70 mg to 109.12 mg for ProCA-30; from 37.50 mg to 76.16
mg for ProCA-31; from 32.60 mg to 60.21 mg for ProCA-32) compared to the old protocol to
yield a significantly higher quantity of ProCA-30, ProCA-31, and ProCA-32. The yield for
ProCA-33 did not increase due to experimental error made during the washing of the Q-column
prior to FPLC injection. Nevertheless, newly modified purification protocol not only allows for
excellent abstraction of the protein from the cell pellet but is also yields a high concentration of
protein absent from DNA or RNA as compared to previous purification results.
In the absence of EGTA sample treatment, all of the discussed members of Class ProCA-3
yield alpha-helical structures that are sustained in the presence and absence of salt in varying
concentrations of magnesium, calcium, gadolinium, and terbium. A high salt environment does
little to destabilize the secondary structure of the protein. Additionally, one can conclude that the
introduction of mutations within the CD binding site does not significantly alter the secondary
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structure of the native form of the protein. Furthermore, the results indicate that the secondary
structure is maintained in the presence of gadolinium under high salt conditions. This is of grave
importance, as it gives insight into the structural stability of the contrast agents. From the
observed CD spectrum analyses, a random coil formation was noted for all variants in the
presence of 5mM gadolinium and terbium in the presence of 5mM EGTA. The denaturation of
the aforementioned proteins is primarily due to a significant decrease in pH due to EGTA
binding gadolinium or terbium.
The relaxivity values obtained for ProCA-30, ProCA-31, ProCA-32, and to lower degree
ProCA-33 seem to be very promising for the future of contrast agents because their relaxivity
values are significantly higher than that of many commercial contrast agents (Tables 5.1 and
5.2). With the exception of ProCA-32 values, the relaxivity values calculated by the traditional
method are nearly identical to those achieved using the fixed gadolinium increasing protein
concentration experiments. Reasons behind this observed phenomenon is not well understood.
Failure to achieve identical relaxivity values for ProCA-32 requires further investigation. From
the fixed 100µM Gd3+-varied protein concentration relaxivity experiments, strong experimental
evidence supports ProCA-30, ProCA-31, and ProCA-32 binding gadolinium in a 1:2 protein to
metal ratio. Studies of ProCA-33 using a reverse titration of the aforementioned binding mode
experiment also allow one to assume that the contrast agent binds two gadolinium ions. The
lower relaxivity values and attenuated or sharp increase in relaxation times for the fixed
gadolinium-varied protein concentration experiments for ProCA-32 and ProCA-33 are likely due
to the heterogeneous nature of the metal binding sites. Dimerization effects or the presence of
residual EDTA present in the sample from our purification process are less likely to explain the
effects observed. Correlating the relaxivity data with the circular dichroism data, it appears that

134

the measured relaxivity values are not necessarily affected by metal-induced structural changes.
Once again, ProCA-32 is the only member of Class ProCA-3 whose increase in relaxivity from
the 1 to 1 to the 1 to 2 ratio under both salt conditions doesn’t correlate significant changes in the
protein’s secondary structure. The remaining members yield positive correlations with the CD
data between their consistent relaxivity values under both salt conditions at 1 to 1 and 1 to 2
ratios.
Future fluorescence experiments will allow one to quantify the experimental metal
dissociation constant of the members of Class ProCA-3. Future relaxivity experiments will be
devoted to metal competition experiments to determine at what concentration gadolinium can be
competed out of the contrast agent binding sites by physiologically relevant metal ions such as
calcium, magnesium, zinc, etc. 1D and NMR diffusion experiments will further characterize the
nature of differentiation between the metal binding sites in class ProCA-3 agents. The results
from these experiments will allow for further screening for an optimal variant that will function
as a contrast agent for MRI diagnostics.
Overall, the studies of this thesis have made a significant contribution to the development of
Class ProCA-3 agents. Because animal experiments and clinical trials require large amounts of
highly concentrated contrast agent of 5mM or higher be injected into an animal or patient for
image-enhancement screening, the optimized purification protocol aids in achieving a pure, high
quantity of contrast agent to be used. The structural stability studies provide insight into the
metal stability of the contrast agents and more specifically into the stability of the agents when
saturated with gadolinium. The higher relaxivity values measured for the contrast agents
compared to commercial analogue Gd-DTPA implies that there is a higher dose efficiency
associated with contrast agent performance, meaning less contrast agent will be required to
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achieve heightened differential signal intensity in an MR image compared to that of the
commercial agents. This is a highly desired result as a lower injection dosage reduces the
potential for the toxic effects associated with the release of a high concentration of free
gadolinium (nephrogenic systemic fibrosis). Combined with future gadolinium-binding studies,
metal selectivity studies, serum stability observations, and in vivo observations of imageenhancement, Class ProCA-3 agents have the potential to be developed as general and targeted
agents, making significant strides in the efficacy of MRI.
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